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ABSTRACT
MYOSIN ISOFORMS AND REGULATION OF TONIC AND PHASIC
CONTRACTION IN SMOOTH MUSCLE
Qian Huang, B.S.
Marquette University, 2012
The contractile properties of smooth muscle (SM) are broadly classified as tonic
and phasic. Among the hypothesized underlying regulatory mechanisms for this
difference is the different actomyosin ATPase kinetic properties of SM SMA/SMB
myosin heavy chain (MHC) isoforms and the preferential expression of SMA and SMB
MHC isoforms in tonic and phasic SM respectively. Thus, we hypothesized that SM
SMA/B MHC expression determines tonic and phasic contractile patterns in SM.
To test the this hypothesis, the role of SMA and SMB MHC isoforms in tonic and
phasic contractions was studied in phasic (longitudinal ileum and stomach circular
antrum) and tonic (stomach circular fundus) smooth muscle tissues of SMB knockout
mice. Knocking out the SMB MHC gene eliminated SMB MHC protein expression and
resulted in up-regulation of the SMA MHC protein without altering the total MHC
protein level. Switching from SMB to SMA MHC protein expression decreased the rate
of the force transient and increased the sustained tonic force in SMB(-/-) antrum with high
potassium (KPSS) or Carbachol (CCh) stimulation. The sustained tonic force in SMB(-/-)
ileum was also significantly increased with KPSS stimulation but not with CCh. The
increased tonic contraction under depolarized condition was not through changes in
second messenger signaling pathways (PKC/CPI-17 or Rho/ROCK signaling pathway) or
LC20 phosphorylation. Biochemical analyses showed that the expression of contractile
regulatory proteins (MLCK, MLCP, PKCδ, and CPI-17) did not change significantly in
tissues tested except for PKCα protein expression being significantly decreased in the
SMB(-/-) antrum. However, specifically activating PKCα with phorbol dibutyrate (PDBu)
was not significantly different in knockout and wild type tissues, with total force being a
fraction of the force generation with KPSS or CCh stimulation in SMB(-/-) ileum and
antrum. Taken together, these data show inhibiting SMB MHC protein expression results
in a compensatory increase in the SMA MHC protein expression and enhanced sustained
tonic contraction with a reduced rate of force generation in these phasic tissues. These
results are consistent with SMA and SMB MHC regulating tonic and phasic contraction
in SM.
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I. Introduction:
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Smooth muscle cells are widely distributed throughout the vertebrate body to
carry out physiological functions in various organ systems including circulation,
digestion, reproduction, respiration, urination, and vision. Their ability to contract and
relax is critical to the functioning of these systems, especially the proper regulation and
extent of contraction and relaxation. Defects in smooth muscle contractile regulation can
lead to clinical diseases, including systematic hypertension, inflammatory bowel diseases,
preterm labor, asthma, bladder outlet obstruction, and vision disorders. Thus,
understanding regulatory mechanism of smooth muscle contraction is of particular
importance.

Overview of myosin
Myosin, a 500kDa protein, is a major component of the contractile apparatus in
eukaryotic organisms. It provides motor function for diverse movement related processes
such as muscle contraction, cell migration and cytokinesis. In eukaryotic cells, myosins
form a super family with at least 18 classes based on phylogenetic analysis of the myosin
head domain (Berg et al., 2001; Sellers, 2000). Based on head and tail domain structures,
analysis of the human genome results in 12 different classes of myosin encoded by ~40
myosin genes (Berg et al., 2001), of which 15 genes encode the conventional class II
myosins (Weiss et al., 1999). The 15 class II human myosin genes encode the skeletal
muscle myosin heavy chains (6 genes), smooth muscle myosin heavy chains (1 gene),
cardiac muscle myosin heavy chains (2 genes), non-muscle myosin heavy chains (3 genes)
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and novel class II myosins (3 genes) (Berg et al., 2001). In addition to different myosin
genes, alternative splicing at the transcriptional level increases the diversity of myosin
molecule isoforms. Thus, it is not surprising that each cell type expresses more than one
myosin heavy chain isoform. In smooth muscle cells at least 4 smooth muscle and 3 nonmuscle myosin isoforms are expressed (Morano, 2003).
In smooth muscle, the functional smooth muscle myosin molecule is a hexameric
protein consisting of two myosin heavy chains (MHCs) and two pairs of non-identical
myosin light chains (MCLs) (Eddinger and Meer, 2007). The MHC with a molecular
weight around 200kDa can be divided into two major functional domains by enzymatic
degradation: a S1 globular head domain and an α-helical rod domain (Lowey et al.,
1969)(see Figure 1). The S1 globular head has ATPase activity and actin binding sites,
which are able to transform chemical energy into the mechanical function of contraction.
The S1 globular head is connected to the α-helical rod by a protease-sensitive region (S2),
and can be subdivided into three proteolytic fragments: a 25kDa fragment, a 50kDa
fragment, and a 20kDa fragment (Mornet et al., 1981)(see Figure 2). The 25kDa fragment
forms part of the ATP- binding site (near Loop 1) (Rayment et al., 1993; Szilagyi et al.,
1979; Walker et al., 1982). The 50kDa fragment is responsible for actin binding. A
prominent cleft separates the 50kDa fragment into upper and lower regions and is the
actin-binding domain (near Loop 2) (Rayment et al., 1993). The 20kDa fragment
includes the MLC
binding sites (Rayment et al., 1993; Szilagyi et al., 1979) (Figure 2B). Functionally,
the S1 globular head can also be divided into three functional domains: motor
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Figure 1. Schematic of smooth muscle myosin molecule and possible smooth muscle
MHC pairings modified from Eddinger & Meer. Am J Physiol Cell Physiol 2007.
A. Schematic of smooth muscle myosin. Smooth muscle myosin molecule consists of two
SM MHCs and two paired MLCs associated with each MHC. As a result of alternative
splicing, four isoforms of MHCs can be found in smooth muscle myosin molecules: SM1,
SM2, SMA, and SMB. SM1 and SM2 MHCs (the tail isoforms) differ at MHC tail region,
where SM1 is 34aa longer than SM2. SMA and SMB MHCs (the head isoforms) differ at
Loop1 of MHC near the ATP binding site, where SMA has an additional 7aa. MLCs
(LC20 and LC17) bind to the level arm of the S1 head.
B. Four possible SM MHCs resulting from alternative splicing at the transcriptional level.
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Figure 2. Schematic of the S1 head modified from Eddinger & Meer. Am J Physiol Cell
Physiol 2007. A. Detailed schematic of the S1 head. The S1 head is composed of three
functional domains: motor domain, lever arm, and converter domain. The motor domain
includes actin binding domain (near Loop 2) and ATP binding domain (near Loop 1).
The lever arm has the MLCs (LC17 and LC20 binding domains). The converter domain
connects the motor domain to the lever arm enabling the relative rotation of lever arm
against the motor domain. B. Linear schematic of the S1 head. Three proteolytic
fragments: 20kDa, 50kDa, and 25kDa. Loop 1 and Loop 2 are proteolytic cleavage sites
and near ATP and actin binding domains respectively. From N-terminus to C-terminus,
the 25kDa fragment is located between the motor domain and the lever arm; the 50kDa
fragment forms the majority of the motor domain; the 20kDa fragment includes converter
domain and lever arm.

	
  
domain, lever domain, and converter domain indicated in Figure 2A (Eddinger and
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Meer, 2007).
The α-helical rod domain of myosin is a coiled-coil rod structure, which is
composed of 28 periodic 7-amino acid repeats (McLachlan and Karn, 1982; McLachlan
and Karn, 1983). This amino acid distribution (Nagai et al., 1988) has been reported to
contribute to the intramolecular MHC coiled-coil rod structure and intermolecular MHC
association of two α-helical rods by hydrophobic interactions, which facilitates the
polymerization of multiple myosin molecules into filaments (McLachlan and Karn, 1982).
Based on the amino-acid sequence, smooth muscle MLCs are divided into two
subtypes: alkali light chains, also named essential light chains (ELCs), which are 17kDa,
and the regulatory light chains (RLCs) which are 20kDa (Matsuda et al., 1981; Miyanishi
et al., 1985). Based on their molecular weights, ELCs and RLCs are also named LC17 and
LC20. Both the light chains belong to the EF-hand protein family, which are able to bind
Ca2+ (Grabarek, 2006). The function of the essential light chain is not totally understood
but is reported to be important for the stability of the α-helical lever arm domains of
MHCs (the 20 kDa fragment of the S1 region) (Dominguez et al., 1998; Trybus, 1994). In
smooth muscle and non-muscle myosin isoforms, LC20 phosphorylation status regulates
the interactions between actin and myosin via LC20 phosphorylation by myosin light
chain kinase (MLCK) (Trybus, 1994) and dephosphorylation by myosin light chain
phosphatase (MLCP) (Somlyo and Somlyo, 2003).
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Smooth muscle myosin belongs to the conventional class II myosin family and is
the major contributor to SM contraction. Similarly, like the other members of class II
myosin family, SM myosin is a hexamer in structure (Figure 1A). Due to the alternative
splicing at the mRNA level different isoforms of SM LCs and SM MHCs are expressed
in smooth muscle. Various combinations of these subunit isoforms lead to the different
myosin isoforms. So far, there are at least 4 SM MHC isoforms identified. SM1 (204
kDa) and SM2 (200kDa) are two SM MHC isoforms originally identified by SDS
polyacrylamide gel (Rovner et al., 1986). The SM1 and SM2 isoforms are identical for
most of the amino acid sequences except in the C-terminus, where SM1 is 34 amino-acid
longer than SM2. SM2 has a unique 9 amino acids (Figure 1). The size differences
between SM1 and SM2 result from a 39-nucleotide insertion with an in frame stop codon
in SM2 mRNA (Babij and Periasamy, 1989; Nagai et al., 1989). The other two SM MHC
isoforms are SMA and SMB. Unlike SM1 and SM2, the differences between SMA and
SMB are located in the S1 head region of SM MHC (Babij et al., 1991; Hamada et al.,
1990; Kelley et al., 1993; White et al., 1993). The splice site is located in mRNA
encoding the 25kDa and 50kDa fragment junction, which is near the ATP binding site
(Rayment et al., 1993). The SMB MHC isoform has an additional 7 amino acids
(QGPSFAY for mouse and rat) compared to SMA. Exon 5b in SM MHC mRNA is
responsible for encoding this additional 7 amino acids in SMB MHC (Babij and
Periasamy, 1989). The 7 amino-acid difference in the S1 head region may be present in
either of the SM1 or SM2 isoforms. Thus the four SM MHC isoforms in smooth muscle
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cells include SM1A, SM1B, SM2A and SM2B (Figure 1B), which could form 10 kinds
of SM myosin molecules by either homodimeric or heterodimeric MHC combinations.
In addition to the SM MHC isoforms, 3 non-muscle MHC (NM MHC) isoforms, NM
MHC A, B, and C are also expressed in smooth muscle cells (Golomb et al., 2004;
Rochlin et al., 1995). NM MHC isoforms A, B, and C are encoded by 3 separate NM
MHC genes distinct from the SM MHC gene (Eddinger and Meer, 2007; Simons et al.,
1991). The three NM MHC isoforms are similar to the SM MHC in size and sequence
except that they do not have the head (7 amino-acid insertion in SMB MHC) or tail insert
(non coiled tail insertion in SM1). NM MHC C isoform is different from NM MHC A
and B in that NM MHC C has an additional 20 amino acids at the N-terminus and has
more variability in amino acid sequence compared to SM MHC (Golomb et al., 2004).
In addition to the presence of different MHC isoforms, different light chain
isoforms (LC17a, LC17b, LC20sm, and LC20nm) are also expressed in smooth muscle cells.
As a result of alternative splicing, two LC17 mRNA are derived from a single gene, which
consists of 7 exons. The difference between the two LC17 mRNAs stems from the
absence of a 44-nt insert (exon 6) at the 3’-end (Lenz et al., 1989). LC17a and LC17b
isoforms have different isoelectric points but are the same size (151 amino acids) and
have identical sequence except for 5 of the 9 amino acids at the C terminus, which can be
separated by two- dimensional polyacrylamide gel electrophoresis. The more acidic
isoform is LC17a, and the more basic isoform is LC17b (Hasegawa et al., 1988). There are
also two isoforms of LC20, SM LC20 (LC20sm) and NM LC20 (LC20nm) in smooth muscle
cells. They are identified by comparing mass spectrometric data from tryptic peptides

	
  
with published cDNA sequence and differential expression patterns in smooth muscle
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and non muscle tissues and encoded by two different genes which are translated to the
same size proteins (171 amino acids), except for 11 amino acids scattered throughout the
sequences (Kumar et al., 1989; Taubman et al., 1987). LC20sm is more acidic than LC20nm
(Eddinger and Meer, 2007; Gaylinn et al., 1989; Inoue et al., 1989).
SM contractions have been described as slow or fast based on their kinetic
properties. The rate of the actomyosin ATPase, the maximal shortening velocity (Vmax)
and the rate of force development and relaxation are three commonly used parameters to
quantify SM contractile kinetic properties. The cross-bridge contractile mechanism (the
mechanism by which myosin attaches and detaches to the actin) which was originally
proposed by the Huxleys and their collaborators (Hanson and Huxley, 1953; Huxley,
1954; Huxley, 1974; Huxley and Hanson, 1954)for skeletal muscle, is widely accepted to
regulate SM contractile properties. It is also believed to be the case that the cross-bridge
contractile mechanism is the major mechanism underlying the diverse kinetic properties
of SM contraction (Horiuti et al., 1989). Thus, unique contractile properties of myosin
and actin in the SM cells could affect SM contractile properties.
The structural differences among SM myosin isoforms result in their different
contractile properties. Studies have shown that the SMB MHC isoform, which has the
additional 7 amino acids near ATP binding site in the S1 head region, has a two-fold
greater ATPase activity than SMA MHC. Thus it is not surprising that the SMB MHC
isoform moves actin filaments approximately 2.5 folds faster than the SMA MHC
isoform in an in vitro motility assay (Kelley et al., 1993; Sweeney et al., 1998). Unloaded
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SMB MHC (~100%) is approximately 10 fold greater than single cells expressing
predominantly SMA MHC in stomach fundus (~85%) (Eddinger and Meer, 2001). It has
also been reported that loss of SMB MHC in mouse bladder decreases smooth muscle
shortening velocity (Babu et al., 2001).
The contractile properties of SM1 and SM2 isoforms are less understood. Based
on studies using antibodies to distinguish the SM1/2 isoforms, the suggestion was made
that the C terminal regions of SM1 and SM2 are essential for filament size and stability
and are able to affect ATPase activity (Horowitz and Trybus, 1992; Kuznicki et al., 1985;
Pagh and Gerisch, 1986; Rovner et al., 1997; Rovner et al., 2002). Due to the longer non
helical tail piece in SM1, the myosin filament formed by SM1 was proposed to be more
stable than SM2 (shorter non helical tail piece isoform) (Meer and Eddinger, 1997;
Rovner et al., 2002). However SM1 and SM2 isoforms move actin filament at the same
rate in the in vivo motility assay (Kelley et al., 1992). In addition, studies from rabbit
aortic and carotid single cells and early stages of pregnant rat uterus suggest that the SM1
and SM2 isoforms may not affect shortening velocity of smooth muscle cells (Meer and
Eddinger, 1997; Morano et al., 1993).
Though smooth muscle NM MHC is quite similar in size and structure to the SM
MHC isoforms, excluding the head and tail inserts appearing in SM MHC, the kinetics of
the NM MHC ATPase are slower than SM MHC. Particularly, the NM MHCA and NM
MHCB ATPase kinetics are slower than SM MHCs (Kovacs et al., 2003; Wang et al.,
2003). This has led some researchers to propose that the NM MHCA and NM MHCB are
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Morano et al., 2000). Because NM MHC expression is very low in most adult SM tissues,
this does not seem physiologically relevant (Eddinger and Meer, 2007).
The myosin light chain isoforms may also affect myosin contractile properties.
The LC17b isoform has been reported to be positively correlated with increased shortening
velocity and ATPase activity (Helper et al., 1988; Malmqvist and Arner, 1991; Morano et
al., 1993). Increasing the expression of LC17a in cultured SMCs increases the rate of force
development and tension production (Huang et al., 1999). However, the contribution of
LC17a/b isoforms to unloading shortening velocity in SM cells and tissues is controversial.
Hasegawa et al. reported that the expression of LC17b is negatively correlated to
actomyosin ATPase activity using reconstituted aortic myosin (Hasegawa et al., 1988).
Similarly, Morano et al. suggested a positive correlation between shortening velocity and
LC17a content in smooth muscle of rat uterus (Morano et al., 1993). However, Kelley et al.
showed that the content of LC17b has no affect on ATPase activity of purified myosin
(mostly SMB) from the turkey gizzard (Kelley et al., 1993). Similarly, Rovner et al.
showed that the in vitro ATPase activity and motility speed of SMB myosin is not
affected by the LC17a/b content (Rovner et al., 1997). Sweeney et al. also failed to find any
correlation between LC17 isoforms and ATPase activity or in vitro motility sliding
velocity of myosin (Sweeney et al., 1998). Work done by Eddinger et al. in isolated
smooth muscle cells showed the unloaded shortening velocity of single smooth muscle
cells is not correlated with the content of LC17a/b in the cell (Eddinger et al., 2000;
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inconclusive.
LC20 phosphorylation is the primary event in initiation of SM contraction
(Adelstein and Conti, 1975). It is reported that phosphorylation of LC20 activates
actomyosin-ATPase activity by regulating the conformational changes of the S1 head
domain, making the myosin more accessible to actin (Baumann et al., 2012; Liu et al.,
2003; Nelson et al., 2005; Rovner et al., 2006; Wendt et al., 1999; Wendt et al., 2001).
The extent of LC20 phosphorylation determines the shortening velocity and tension
development (Hai and Murphy, 1989).
Based on the discussion above of published data, the different contractile
properties of myosin (including Vmax, actomyosin ATPase, and the rate of force
development and relaxation) are primarily determined by different MHC isoforms. The
effect of different LC isoforms (both LC17 and LC20) on the contractile properties of
myosin is minor and inconsistent and does not appear to be relevant.

Second messenger pathways

As mentioned above, there are reports that the different SM myosin isoforms are
expressed uniquely in smooth muscle cells (SMC) and this may affect the contractile
function of SMCs and tissues. Uniquely expressed SM MHC isoforms may be part of
distinct contractile systems targeted by different secondary messenger signaling pathways
most likely acting on regulation of LC20 phosphorylation (Figure 3). While LC20
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12	
  

tissues, it is believed to be a prerequisite for smooth muscle activation of myosin ATPase
activity and generation of force (Butler et al., 1983; Dillon et al., 1981; Persechini and
Hartshorne, 1981). The balance of kinase activities (to phosphorylate LC20) and myosin
light chain phosphatase activities (to dephosphorylate LC20) determines LC20
phosphorylation levels (Kamm and Stull, 1985; Somlyo and Somlyo, 2003).

a. Phosphorylation of LC20

Several kinases are reported to be able to phosphorylate LC20 in vivo and in vitro.
Of these, myosin light chain kinase (MLCK) is the most extensively studied and also
reported to be the primary physiological LC20 kinase in smooth muscle tissues. MLCK, a
serine/threonine protein kinase, can be activated by Ca2+/calmodulin (CaM) and
phosphorylates Serine-19 in LC20, which leads to increased ATPase activity and force
production (Gao et al., 2001). Biochemical analysis indicates that MLCK consists of a
catalytic domain, a Ca2+- CaM binding domain, and several actin and myosin binding
domains (Barden et al., 1996; Hong et al., 2011; Kanoh et al., 1993; Sellers and Pato,
1984; Silver et al., 1997; Sobieszek, 1985). Based on the MLCK sequence, MLCK is
proposed to be an elongated and flexible molecule capable of binding to both the actin
and myosin filaments (Kanoh et al., 1993; Silver et al., 1997). In the absence of Ca2+CaM, MLCK is catalytically inactive by auto-inhibition. Under excitatory conditions,
elevated cytosolic free Ca2+ ([Ca2+]i) binds to CaM. Ca2+-CaM triggers the
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Figure 3. Schematic diagram of cellular signaling pathways regulating smooth muscle
contraction (From Ratz et al., Am J Physiol Cell Physiol 2005). Depolarization opens
voltage gated Ca2+ channels on the smooth muscle cell membrane such as VoltageOperated Calcium Channel (VOCC), and store-operated Ca2+ channel (SOCC) and
increases [Ca2+]I by allowing the influx of extracellular Ca2+. The elevated [Ca2+]I then
binds to CaM and activates MLCK which phosphorylates LC20 on myosin. The
phosphorylated LC20 triggers conformational change of the myosin head to make myosin
more accessible to actin filaments, thereby initiating the actomyosin cross-bridge cycling.
Furthermore, actin filaments are connected to the cell membrane, extracellular matrix and
cytoskeleton by adhesion proteins such as integrin, vinculin et al and dense bodies in the
cell. The myosin sliding on actin filaments as a result of actomyosin cross-bridge cycling
leads to smooth muscle contraction. G protein coupled receptor (GPCR) agonists such as
norepinephrine (NE) can also regulate [Ca2+]I by activating G proteins. Activated G
proteins further activate PLCβ, which hydrolyzes PIP2 on the cell membrane to inositol
1,4,5-trisphosphate (IP3). IP3 binds to IP3 receptors on the sarcoplasmic reticulum (SR),
and release the SR Ca2+ to the cytoplasm, which further opens ryanodine receptors
(activated by Ca2+) on SR releasing more Ca2+.. MLCK mediated LC20 phosphorylation is
Ca2+ dependent or Ca2+ sensitive. On the other hand, in order for LC20 to maintain its
phosphorylation status, the activity of myosin light chain phosphatase (MLCP) needs to
be inhibited. However, neither the activation or inactivation of MLCP requires [Ca2+]I.
Therefore, it is Ca2+ independent or insensitive. Agonists induced contraction activates
Ca2+ dependent LC20 phosphorylation by increasing [Ca2+]I (as mentioned above), and
inhibits MLCP activity which is Ca2+ independent by activating either PKC/CPi-17
signaling pathway or Rho/ROCK signaling pathway.
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LC20 and ultimately phosphorylate LC20(Barden et al., 1996). The increased [Ca2+]i is
either from the influx of extracellular Ca2+ via depolarizing smooth muscle cells opening
of voltage gated Ca2+ channels on the cell membrane, or agonist induced G protein
signaling pathway mediated Ca2+ release from the sarcoplasmic reticulum (SR)
(Himpens et al., 1995; Karaki, 2004; Lee et al., 2002; McFadzean and Gibson, 2002).
Thus, LC20 phosphorylation depends on MLCK in a Ca2+ sensitive manner (Barron et al.,
1979; Hathaway and Adelstein, 1979; Rosenfeld et al., 1998; Trybus et al., 1994)(Figure
3). In addition to MLCK, other kinases such as integrin-linked kinase (ILK), zipperinteracting protein kinase (ZIPK), Rho-associated kinase (ROCK) have also been
reported to phosphorylate LC20 (Amano et al., 1996; Niiro and Ikebe, 2001; Wilson et al.,
2005).

b. Signaling pathways regulating myosin phosphatase
Myosin light chain phosphatase (MLCP) is a trimeric enzyme capable of
dephosphorylating LC20. MLCP consists of a regulatory subunit -myosin phosphatase
target subunit 1 (MYPT1), a catalytic subunit -PP1cδ, and a 20 kDa subunit whose
function is unknown (Hartshorne et al., 1998). The signaling pathways regulating MLCP
activity can be divided into two groups: (1) MLCP inhibiting and (2) MLCP activating.
Inhibition of MLCP activity can increase generation of force in smooth muscle by
allowing an increase in LC20 phosphorylation even in the absence of increased basal
kinase phosphorylation of LC20. The LC20 phosphorylation level is dependent on the ratio
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kinase activity level, the activity of MLCP determines the extent of LC20 phosphorylation,
which correlates with the extent of smooth muscle force production at certain levels of
phosphorylation. Thus, in order for smooth muscle to generate force, the MLCP activity
needs to be less than the kinase activity. On the other hand, in order for smooth muscle to
relax, the MLCP activity must be greater than the kinase activity. Neither inhibition nor
activation MLCP activity appears to require participation of Ca2+. Thus, unlike MLCK
activation or inactivation of smooth muscle contraction or relaxation determined by
[Ca2+]i (Ca2+ dependent), force enhancement or inhibition resulting from altered MLCP
activity is reported to be Ca2+ insensitive or Ca2+ independent (Hori and Karaki, 1998).
Thus, the regulation of LC20 phosphorylation and corresponding force generation involve
both Ca2+sensitive (MLCK) and insensitive (MLCP) regulatory pathways (Ratz et al.,
2005)(Figure 3).

Based on MLCP structure, its activity can be regulated via MYPT1 and PP1cδ,
which are the targets of signaling pathways that inhibit MLCP activities. MYPT1 cannot
only activate MLCP by targeting MLCP to LC20 but it can also enhance MLCP catalytic
activity by binding to PP1cδ, the catalytic subunit of MLCP (Alessi et al., 1992; Shimizu
et al., 1994). Studies indicate that the small GTPase Rho and its target Rho associated
kinase (ROCK) signaling pathway is able to phosphorylate inhibitory sites on MYPT1
and inactivate MLCP in smooth muscle (Kimura et al., 1996). RhoA is a monomeric
GTPase and can be activated by extracellular G-protein coupled receptor binding in
smooth muscle contraction (Gong et al., 1996). Activated RhoA is reported to translocate

	
  
to the cell membrane and activate ROCK tethered there. ROCK is a serine/threonine
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kinase protein and is believed to regulate multiple cellular functions including motility,
proliferation, and apoptosis in many cell types (Guilluy et al., 2011; Street and Bryan,
2011). For smooth muscle cells, ROCK is also involved in regulating cell contraction.
When activated, the serine/threonine kinase activity of ROCK is able to phosphorylate
MYPT1 at Threonine-696 and Threonine-853 inactivating MLCP (Feng et al., 1999).
Similarly, MLCP can also be inactivated by inhibiting the activity of its catalytic subunit,
PP1cδ. When activated, potentiated PP1 inhibitory protein of 17 kDa (CPI-17 activated
by PKC not MLCK) acts as a pseudo-substrate of MLCP by binding to PP1cδ and
competing with LC20 for phosphorylation (Eto et al., 2004). Thereby, CPI-17 inactivates
MLCP by targeting PP1cδ. Activation of CPI-17 is regulated by phosphorylation of
Threonine-18 on CPI-17. Protein kinase C (PKC) is the major kinase to phosphorylate
CPI-17. PKC is activated by diacylglycerol (DAG), which is produced through agonists
stimulation GTP coupled protein signaling pathways. Thus the inhibitory phosphorylation
of MYPT1 and PP1cδ are significantly mediated by the Rho/ROCK and PKC/CPI-17
pathways respectively. However more and more in vivo and in vitro evidence suggests
that in the process of smooth muscle contraction there is crosstalk between the
Rho/ROCK and PKC/CPI-17 pathways to fine tune MLCP activity. This enables smooth
muscle tissues to display diverse contractile patterns. The most direct evidence is that
apart from PKC, ROCK is also capable of activating CPI-17 (Koyama et al., 2000).
Likewise, it has also been demonstrated that PKC can mediate activation of ROCK in
porcine coronary artery spasm (Kandabashi et al., 2003). Furthermore, other kinases
(ZIPK, ILK, protein kinase N (PKN)), upstream of MLCP also exhibit inhibitory
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phosphorylation of MLCP. The significance of the role they play in controlling smooth
muscle contraction in vivo is unknown and still under investigation (Hamaguchi et al.,
2000; MacDonald et al., 2001; Ohama et al., 2003).
Compared to the Rho/ROCK and PKC/CPI-17 MLCP inhibitory pathways, the
signaling pathways that activate or promote MLCP activity are less well understood. The
nitric oxide (NO) pathway is the most studied signaling pathway that relaxes smooth
muscle contraction. The postulated mechanism for NO mediated smooth muscle
relaxation includes inhibiting the Rho/ROCK pathway and counteracting its inhibitory
phosphorylation on MYPT1. NO is able to increase the intracellular level of cGMP which
activates PKG (cGMP-dependent protein kinase). Activated PKG inactivates RhoA by
phosphorylating RhoA at Serine-188. Moreover, activated PKG also phosphorylates
MYPT1 at Serine-695, which activates MLCP and prevents inhibitory phosphorylation at
Threonine-696 on MYPT1 at the same time (Wooldridge et al., 2004). Telokin, an
exclusively expressed smooth muscle protein, is identical to the C terminus of MLCK but
with much smaller size. It has been reported to be involved in promoting MLCP activity
when it is activated by an unknown mechanism (Khromov et al., 2006). Therefore,
MLCP activity appears to be regulated by a network of signaling pathways to modify the
SM contractile response.

c. Other regulatory mechanisms regulating smooth muscle contraction

It is widely accepted that phosphorylation of LC20 is not the only mechanism
regulating smooth muscle contraction. The contractile properties of smooth muscles are
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broadly classified as tonic and phasic. Upon stimulation, tonic smooth muscle is able
to maintain sustained high force level whereas phasic smooth muscle exhibits a rapid
transient force generation followed by a decrease in force to a low level (Somlyo and
Somlyo, 1968). The differences between tonic and phasic contractile patterns cannot be
explained by the time course of [Ca2+]i or phosphorylation of LC20 upon stimulation. In
both phasic and tonic smooth muscles, the [Ca2+]i and phosphorylation of LC20 increase
rapidly upon stimulation and then decrease to an intermediate steady state (Dillon et al.,
1981; Rembold and Murphy, 1986). The same thing occurs with the maximal shortening
velocity (Vmax). Vmax rapidly increases to the maximal value upon stimulation then
decreases to an intermediate level. In phasic smooth muscle, force generation patterns
follow the [Ca2+]i and phosphorylation levels of LC20. However, in tonic smooth muscle,
after initial force activation, despite decreases in [Ca2+]i and dephosphorylation of LC20 to
submaximal levels, force can be maintained at a sustained high level. This force
maintenance with low [Ca2+]i, LC20 phosphorylation and Vmax is referred to as the “latch
state” (Dillon et al., 1981; Hai and Murphy, 1988; Rembold and Murphy, 1986). The
mechanism underlying the latch state is unknown. Several regulatory mechanisms have
been hypothesized including cytoskeletal remodeling (Gerthoffer and Gunst, 2001; Hu et
al., 2007; Kim et al., 2008; Mehta and Gunst, 1999; Pavalko et al., 1995), second
messenger pathway regulation of MLCK/MLCP activity (Harnett et al., 2005; Jiang and
Morgan, 1987; Poole and Furness, 2007; Rattan et al., 2006; Sohn et al., 2001; Urban et
al., 2003), altered kinetics of phosphorylated vs. dephosphorylated myosin cross-bridges
(Dillon et al., 1981; Hai and Murphy, 1989), and the kinetic properties of actomyosin
ATPase of different myosin isoforms (NM myosin and SM myosin) (Fuglsang et al.,

	
  
1993; Khromov et al., 1995; Kovacs et al., 2007; Lofgren et al., 2003; Morano et al.,
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2000; Rosenfeld et al., 2003; Wang et al., 2003).

An actin related cytoskeletal remodeling mechanism has been suggested to be
involved in regulating tonic and phasic contractions as changes in the quantity of actin
filament (F-actin) would be proportional to force generation. Thus regulatory proteins
and corresponding signaling pathways controlling actin stability and polymerization may
play a role in different smooth muscle contractile patterns including tonic and phasic
contractions. Haeberle reported that in vitro motility of unphosphorylated and
phosphorylated myosin purified from chicken gizzard is affected by actin polymerization,
which may suggest a role of actin in regulating tonic contraction (Haeberle, 1999). Work
from Gunst’s group studying tracheal smooth muscle contraction also suggested that
actin filament stability and dynamics are critical for tonic contraction (Gerthoffer and
Gunst, 2001; Mehta et al., 1998; Mehta and Gunst, 1999). Thus proteins regulating actin
polymerization such as cofilin, RhoA, and Arp2/3 complex may also be able to regulate
smooth muscle contraction (Zhang et al., 2005; Zhang et al., 2010; Zhao et al., 2008).
However, a study from Bednarek et al. indicated that the changes in actin polymerization
do not alter tonic and phasic contractions differently, suggesting that the effect of actin
filament stability on both the tonic and phasic contractions are the same (Bednarek et al.,
2011). Therefore, the inconsistent results from the studies of actin filament stability in
smooth muscle contraction indicate that the actin related cytoskeletal-remodeling
mechanism might not be sufficient to explain tonic and phasic contractions.

The involvement of differentially recruited secondary messenger signaling
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pathways is another mechanism proposed to explain tonic and phasic contractions. As
mentioned above, the key event in secondary messenger signaling pathway mediated
smooth muscle contraction is LC20 phosphorylation, the status of which is determined by
MLCK/MLCP activities. It has been suggested that the sustained force is due to the high
level of LC20 phosphorylation via inhibiting MLCP activity during tonic contraction in
comparison with phasic contraction. The mechanism underlying is that for both the tonic
and phasic contractions, upon stimulation, [Ca2+]I increases, which activates MLCK.
Activated MLCK then phosphorylates LC20. At the same time MLCP activity is inhibited
to prevent phosphorylated LC20 from being dephosphorylated. The high MLCK activity
vs. low MLCP activity leads to high level of LC20 phosphorylation. During this process,
force is initiated and continues to increase until the point when [Ca2+]I begins to decrease
to a intermediate level. Accordingly, Ca2+ dependent MLCK activity also decreases.
During this time MLCP continues to be inhibited in tonic contractions whereas MLCP is
not inhibited or may be activated in phasic contraction. Though decreased MLCK activity
results in less LC20 phosphorylation, the inhibited MLCP is unable to dephosphorylate
already phosphorylated LC20, therefore, the LC20 phosphorylation level remains high and
results in a high level of sustained force in tonic contraction. For the phasic contraction,
decreased MLCK and activated MCLP activities decrease LC20 phosphorylation, which
results in force falling to a low level. This mechanism fails to elucidate the low LC20
phosphorylation and high level of sustained force in tonic contraction. Furthermore,
which secondary signaling pathway regulates tonic contraction is uncertain. Involvement
of PKC/CPI-17signaling pathways mediated tonic contraction is supported by the
following studies: Jiang et al., reported that the PKC/CPI-17 signaling pathway is able to
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Work from Sohn et al., suggested that PKCε is responsible for maintenance of tonic tone
induced by PGF2α or a thromboxane analog in lower esophageal sphincter (LES) (Sohn
et al., 2001). Poole et al., reported that PKCδ isoform is able to enhance tonic contraction
in guinea pig ileum (Poole and Furness, 2007). However, it has also been reported that
the Rho/ROCK signaling pathway may be responsible for tonic contraction. Urban et al.,
showed that activation of the Rho/ROCK signaling pathway is involved in the tonic
contraction of femoral and renal arterial smooth muscle (Urban et al., 2003). Others have
also reported that RhoA might be involved in sustained contraction of LES (Harnett et al.,
2005). Rattan et al. demonstrated in single smooth muscle cells that Rho/ROCK plays a
critical role in the rat internal anal sphincter (IAS) tonic contraction (Rattan et al., 2006).
Thus, the inability to explain the relation of a low level of LC20 phosphorylation and high
level maintained force in tonic contraction and the inconsistent results obtained in
different smooth muscle tissues leave unresolved the proposal that a mechanism that
differentially recruits secondary messenger pathways is a major factor in determining
tonic and phasic contractions.

The altered kinetics of phosphorylated vs. dephosphorylated myosin cross-bridges
was proposed by Murphy and colleagues to elucidate the mechanism underlying tonic
and phasic contractions (Dillon et al., 1981; Hai and Murphy, 1989). They hypothesized
that cross bridge phosphorylation (phosphorylation of LC20) is required for cross bridge
attachment, but that dephosphorylating of an attached cross bridge reduces its detachment
rate. Both the phosphorylated and dephosphorylated cross bridge are capable of
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with intermediate levels of LC20 phosphorylation. As mentioned previously, LC20
dephosphorylating occurs via MLCP, which is Ca2+ independent. Therefore, in this
scenario, the low [Ca2+]i does not affect the ability to maintain force at high level in tonic
smooth muscle. However, Murphy and colleagues(Hai and Murphy, 1989) determined
that phosphorylated cross bridge is fast cross bridge and dephosphorylated cross bridge is
slow cross bridge based on the study from Gorecka et al. (Gorecka et al., 1976), which
reported that the ATPase activity of smooth muscle actomyosin is proportional to LC20
phosphorylation. But covalent phosphorylation modification of LC20 imposes an ATP
cost that appears inconsistent with the extraordinary economy of force maintenance (Paul,
1989). A mechanical distinction between phosphorylated and dephosphorylated cross
bridges remains unsolved. A better way to test phosphorylated and dephosphorylated
cross bridge mechanics needs to be developed.

The expression of different MHC isoforms in smooth muscles and relevance to tonic
and phasic contractions.

As mentioned above there are different myosin isoforms with distinct contractile
kinetics expressed in smooth muscle. The tonic and phasic contractile patterns may be
caused by different myosin isoforms. The contractile properties of the smooth muscle
myosin isoforms are determined by its subunits, the MHCs and LCs. There appears to be
a preponderance of evidence that the contractile kinetic properties of smooth muscle
myosin are LC17 isoform independent for both in vitro and in vivo measurement
(Eddinger et al., 2000; Eddinger and Meer, 2001; Kelley et al., 1993; Rovner et al., 1997;
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Sweeney et al., 1998). No functional differences for the two LC20 isoforms have been
definitively identified either. Therefore, the role of smooth muscle myosin isoforms in
determining tonic and phasic contractions would need to be primary dependent on the
properties of MHC isoforms. There are seven MHC isoforms present in smooth muscle
including four SM MHCs (SM1, SM2, SMA, and SMB) and three NM MHCs (NM
MHCA, B, and C, however MHCC not expressed in SM to any significant amount).
There have been reports supporting the expression of the NM MHCB isoform with tonic
contractions. The kinetics of actomyosin ATPase of NM MHCB have been reported to
be slower than the other seven MHC isoforms (Wang et al., 2003). In the presence of
actin, NM MHCB has high ADP affinity and a low rate of ADP release, which enables
NM MHCB to attach to actin for an extended period (Rosenfeld et al., 2003). The actinmyosin- ADP of NM MHCB requires mechanical strain to release ADP. With tonic force
maintenance, the long attachment time of NM MHCB to actin could explain the latch
cross bridge(Kovacs et al., 2007). Studies from Morano et al. showed that bladder
smooth muscle from SM MHC knockout mice generates a slow tonic contraction,
whereas the wild type bladder smooth muscle develops a phasic contraction (Morano et
al., 2000). A subsequent study from Lofgren et al. supports the role of NM MHCB in the
tonic contraction by showing that [Ca2+]I levels are the same between knockout and wild
type bladders and the Vmax of knockout bladder smooth muscle is more ADP sensitive
than wild type bladder (Lofgren et al., 2003). Thus tonic contraction could result from
expression of the NM MHCB isoform. However, the expression of NM MHCB is
developmentally regulated and tissue specific (Eddinger and Murphy, 1991; Eddinger
and Wolf, 1993; Phillips et al., 1995; Tullio et al., 1997). In the adult wild type mouse
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tonic contraction continues to be present. In the adult rabbit tissues, the expression of
non-muscle myosin is undetectable, however the tonic contractions are still present
(Eddinger and Meer, 2007; Giuriato et al., 1992; Han et al., 2006). Thus, the non-muscle
myosin isoforms including NM MHCB may not be the major regulator for tonic
contractions in adult animals due to their low expression level in these animals.

The tail isoforms of smooth muscle myosin (consisting of SM1 and SM2 SM
MHC isoforms) also seem unlikely to be the primary factor in tonic contractions. The
SM1-to-SM2 ratio is uncorrelated to distinct contractile kinetics including unloaded
shortening velocity and force generation. Studies carried out by Sparrow et al. in skinned
rat myometrial muscle indicated SM1 is positively related to shortening velocity. Nonpregnant rat myometrium smooth muscle tissue with higher SM1/SM2 ration has higher
Vmax than non-pregnant rat which has lower SM1/SM2. However when studied with
skinned fibers, they obtained a contradictory result that Vmax of Non pregnant rat uterine
smooth muscle fiber is lower than Vmax of the uterine smooth muscle of pregnant rat
(Sparrow et al., 1988). Furthermore, studies using either intact smooth muscle tissues or
single smooth muscle cells from variety of smooth muscle organs all fail to find distinct
physiological functions of the SM1 and SM2 isoforms (Cai et al., 1995; Kelley et al.,
1992; Meer and Eddinger, 1997; Morano, 2003). Results from SM2 knockout mouse
bladder and aortic smooth muscles showed enhanced contractility suggesting that SM2
may negatively regulate smooth muscle contraction (Chi et al., 2008). But this conclusion
does not take into account possible results from down regulated SM1 and reduced thick
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filament with the loss of SM2. In addition, no distinct expression patterns of SM1 and
SM2 are reported in tonic or phasic tissues. Rovner and Murphy reported that the SM1
and SM2 are equally expressed in swine carotid and stomach (Rovner et al., 1986). Other
studies suggested the SM1:SM2 ratio in different tissues varies within a narrow range
from 40:60 to 60:40 (Borrione et al., 1989; Eddinger and Murphy, 1991; Kuro-o et al.,
1989; Murakami and Elzinga, 1992; Szymanski et al., 1998). To date, no results have
been reported clearly demonstrating that SM1 and SM2 expressions are tonic and phasic
tissue related.

In contrast to the SM1 and SM2 isoforms, the expression of SMA and SMB
MHC isoforms (the head isoforms) are expressed preferentially in tonic and phasic
tissues. It is reported that the mRNA and protein of SMB MHC isoform is predominantly
expressed in visceral smooth muscle tissues including colon, ileum, veins such as the
vena cava and saphenous, and bladder, which are all phasic tissues (Eddinger, 2009; Han
et al., 2006; Rondelli et al., 2007; White et al., 1993). The mRNA and protein of SMA
MHC isoform is primarily found in elastic arteries such as aortic, renal and femoral artery,
and the uterus, which are tonic tissues(Babij, 1993; Eddinger et al., 2007; Han et al., 2006;
Rondelli et al., 2007). Even within a single tissue, the expression of SMB and SMA
MHC isoforms are different. In the rabbit stomach tissue, approximately 90% of phasic
antrum SM MHC mRNA is the SMB MHC, whereas 90% of tonic fundus SM MHC
mRNA is the SMA MHC (Eddinger and Meer, 2001). It appears that SMA /SMB MHC
expression is tonic/phasic-tissue specific. Furthermore, the seven amino-acid insertion in
the S1 head of SMB MHC makes myosin ATPase activity approximately twofold greater
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other hand, the slow ATPase activity of SMA MHC is also consistent with the kinetic of
tonic contraction which has a five times higher MgADP affinity and 3 times lower
second- order rate constant for MgATP than SMB MHC (Dillon et al., 1981; Somlyo et
al., 1998). Thus it is reasonable to postulate the existence of physiological relevance of
SMA and SMB MHC expression to tonic and phasic contractile patterns in corresponding
smooth muscle tissues. In an effort to investigate this hypothesis, several research articles
have been published based on a SMB knockout mouse model. The results of this work
from Periasamy and others showed that SMB knockout bladder and trachea produce
significantly less force than wild type tissues. Similarly, the shortening velocity of SMB
knockout tissues is also slower than wild type controls (Babu et al., 2001; Tuck et al.,
2004). Studies from the same group but using different tissues (aorta and mesenteric
vessels) demonstrated that the SMB knockout tissues are able to produce more force than
wild type tissues. Likewise, the shortening velocity of SMB knockout tissues are
decreased compared to wild type controls (Babu et al., 2004). However, since the
expression of SMB MHC in wild arterial tissues is only trace amounts, the SMB
knockout in these tissues does not result in any significant SMA/B MHC expression shift
between SMB knockout and wild type tissues. They concluded the decreased contractility
in the SMB knockout tissues is due to the increased expression of thin filament regulatory
proteins calponin, microtubule affinity regulating kinase (MARK), and caldesmon (Babu
et al., 2004). Results from Patzak et al. using the same animal model reported that there
is not a correlation between SMB MHC expression and the rate of force generation in
perfused afferent and efferent renal arterioles (Patzak et al., 2005). Hypolite et al.
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reported that compared to wild type, the loss of SMB MHC in detrusor smooth muscle
increases contraction due to the up-regulation of the PKC mediated signaling pathway
(Hypolite et al., 2009).

The results of studies done on the same animal model from different groups in
different tissues appear inconsistent. Thus the role of SMA/B MHC isoforms in SM tonic
and phasic contractions remains unresolved. The focus of the above reports on the SMB
knockout mouse is primarily on the role the SMA/B MHC isoforms play in the peak
force generation (phasic component) and shortening velocity of smooth muscle tissues.
They did not investigate the relationship between SMA/B MHC isoforms and sustained
force maintenance in tonic contraction, which is the primary characteristics
distinguishing tonic and phasic contraction. Thus, the question of the contractile patterns
(tonic and phasic) and their relationship with SMA/B MHC isoform expression remains
to be addressed. The SMB knockout mouse model is a good model to examine this
question.

The objective and the significance of the project

Smooth muscle is specialized to generate force and shortening and is responsible
for the contraction of hollow organs including the gastrointestinal tract, bladder, uterus
and blood vessels. The contraction of smooth muscle needs to be precisely regulated to
ensure different spatiotemporally physiological functions including food digestion in the
intestine, urine storage in the bladder, and blood pressure maintenance in blood vessels.
Since it was postulated more than half a century ago, the Huxley’s sliding filament theory

	
  
has shed light on the mechanism of muscle contraction (Huxley, 1954; Huxley and
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Hanson, 1954). For over three decades, it has also been known that unlike skeletal muscle,
the phosphorylation of LC20 on the SM myosin head is a pivotal and unique covalent
modification of smooth muscle myosin that regulates contraction (Sobieszek, 1977).
However, force generation is not always proportional to the level of LC20
phosphorylation. In certain smooth muscle tissues (tonic smooth muscle), force may be
maintained at a high level for minutes to hours, while phosphorylation of LC20 is
decreased to near basal level. This state has been referred to as the “latch state”. The LC20
phosphorylation mechanism is insufficient to explain this. The mechanism for force
maintenance in tonic contraction compared to phasic contraction is not clear. Based on
the previous discussion, the SMA/B MHC isoforms may be involved in tonic and phasic
contractions. The unique tissue distribution and kinetics of actomyosin ATPase activity
of the SMA and SMB MHC isoforms may contribute to tonic and phasic contractions.
SMA and SMB myosin isoforms may generate their unique contractile patterns in
different tissue types.

The objective of this project is to test the hypothesis that SM SMA and SMB
MHC isoforms are responsible for regulating tonic and phasic contractions respectively
in smooth muscle. To evaluate this hypothesis, three specific aims were carried out (1) To
determine if SMB MHC expression is required for smooth muscle to exhibit phasic
contraction, or phasic charateristics. (2) Investigate if replacing SMB MHC with SMA
MHC isoform is able to cause a tonic contraction or tonic characteristics in a phasic
tissue where SMB MHC is predominantly expressed. (3) Examine in addition to
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SMA/SMB MHC isoforms, if the secondary messenger pathways are also involved in
regulating tonic and phasic contractions. To do these studies, we utilized a SMB MHC
knockout mouse kindly provided by Drs. Babu and Periasamy (Babu et al., 2001).

This project is of significant importance in the following aspects: (1) As
discussed previously, six research articles have been published using the SMB knockout
mouse model, but the results does not directly address the possible role of the SM
SMA/B MHC isoforms on tonic and phasic contraction. This project looked directly at if
and how expression of the SMA/B MHC isoforms relates to tonic and phasic contraction
in smooth muscle. (2) The latch cross- bridge and latch state has been proposed for long
time to explain the sustained force maintenance with low ATPase activity, LC20
phosphorylation, and [Ca2+]I (Dillon et al., 1981; Rembold and Murphy, 1986). However,
how the latch state is achieved and why the latch state only appears in some smooth
muscle tissue remains unresolved. This project tested whether SMA/B MHC isoform
expression can explain the sustained force production (latch state) in SM. (3) The
contraction of smooth muscle plays a vital physiological function in various systems
including gastrointestinal, cardiovascular, reproductive and respiratory systems. The
regulation of smooth muscle contraction is a complicated network composed of various
regulatory mechanisms (secondary messenger signaling regulation, cytoskeleton
regulation, cross-bridge cycling regulation etc.). Understanding the regulation of tonic
and phasic contractile patterns will provide insight to smooth muscle contraction
regulatory mechanisms. Additionally, defects of smooth muscle contraction in many of
these systems can lead to clinical diseases, including inflammatory bowel diseases,

	
  
systematic hypertension, preterm labor, chronic pulmonary obstructive disease, and
asthma. It is reported that the expression of SMB MHC is significantly reduced in
precapillary hypertensive rats. Thus, the understanding of regulatory mechanisms that
control smooth muscle contraction may provide targets for the development of
therapeutics to treat these diseases.
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A. Mouse strains:
The B6/129 wild type and SMB(-/-) mice (Babu et al., 2001), 22-25weeks old,
were used for all the experiments. All the animals used in this project were approved by
the Marquette Institutional Animal Care and Use Committee (IACUC) under protocol
number AR-221.

B. Polymerase chain reaction (PCR) genotyping:
SMB (+/-) mice, generously provided by Dr. Periasamy, were crossed to produce
wild type and SMB(-/-) offspring. Wild type, SMB (+/-) and SMB (-/-) mice genomic DNAs
were extracted from tail clips. 0.5 cm mice tail tips were clipped and digested in a
digestion buffer (0.5% Tween 20, 1.0mM EDTA pH 8.0, 50mM Tris base pH 8.0) with
0.8g/L proteinase K overnight at 55°C. Proteinase K was inactivated by heating at 99°C
for 5 minutes. Mouse genomic DNA was isolated using 14,000 revolutions per minute
(rpm) centrifugation for 5 minutes and used as PCR templates. The PCR reaction system
and cycles were as follows: All PCR reactions were conducted in a 50µl, containing 1.0µl
700ng/µl DNA template, 5.0µl 10X platinumTaq polymerase buffer, 1.5µl 1.5mM MgCl2,
1.0µl 10mM dNTP mix, 0.2µl Platinum Taq (Invitrogen, Carlsbad, California) and 2.0µl
100µM primer mix (WT forward: 5’-CAA GGT CCA TCT TTT GCC TAC-3’, WT
reverse: 5’-GCA ATC CAT CCA GGC TGG AGT-3’, KO forward: 5’-GGC ACA ACA
GAC AAT CGG CT-3’, KO reversed: 5’-ACT TCG CCC AAT AGC AGC CA-3’:

	
  
Operon, Alameda, CA). The DNA templates were melted at 94°C for 2 minutes and
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followed by 44 amplification cycles: 94°C denaturation for 30 seconds, 55°C annealing
for 30 seconds and 72°C extension for 1 minute. The end products were stored at 4°C.
The Ericomp thermoelectric thermocycler (Scientific Plastics, Kansas City, KS) was used
as PCR apparatus. The PCR products generated with WT primers and KO primers are
245bps and 219bps, which correspond to SMB MHC mRNA 5b exon and PGK promoted
neomycin mRNA respectively.

C. Tissue preparations:
Mice were euthanized by Carbon Dioxide (CO2). Stomach tissues (fundus,
antrum) and ileum were isolated, cleaned of blood, adipose and chyme and kept in
physiological salt solution (PSS: 4.7mM KCl, 140mM NaCl, 1.2mM Na2HPO4, 2.0 mM
3-(N-morpholine) propanesulfonic acid (MOPS), 0.02mM ehtylenediaminetetraacetic
acid (EDTA), 1.2mM MgSO4, 1.6mM CaCl2, 5.6mM glucose, pH 7.4 at 37°C) at 4°C
until processed (no longer than 24 hours).

D. Electrophoretic Analysis:
1. DNA electrophoresis:
3µl Loading dye (2.5 g/L bromophenol blue, 400g/L sucrose)(6x) mixed with
15µl of PCR products were loaded into 1.5% agarose gel pre-stained with 0.2µg/ml
ethidium bromide and run at 100 volts for 30 minutes. Tris-acetate-EDTA buffer (TAE:
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40mM Tris base, 20mM acetic acid, 1mM EDTA) was used as the buffer system. The
results of DNA electrophoresis were visualized and images were captured on a U.V.
trans-illuminator (Voytas, 2001).

2. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE):
SDS-PAGE gels were made using the methods of Giulian et al (1983). 50mg
Fundus and antrum tissues without mucosa were homogenized in 1ml sample buffer
(0.0625M Tris pH 6.8, 0.1% (v/v) sodium dodecyl sulfate (SDS), 15%(w/v) glycerol.
0.01%(w/v) bromophenol blue, 15mM dithiothreitol (DTT)) using a glass pestle and
boiled at 100°C for 5 minutes followed by centrifugation at 13000 rpm for 10 minutes.
The supernatant was collected as samples for protein analysis. 50mg/ml samples were
loaded onto 8cmx10cmx1mm 15% polyacrylamide gels. Based on the preliminary
protein loading standard curves, the loading volume for analyzing proteins was: β actin,
PKCα, SMB MHC, SMA MHC, total myosin heavy chain (SM+NM), LC20,
phosphorylated LC20 - 15µl per lane, for MLCK and MYPT1 - 30µl per lane and for
PKCδ, NM myosin, and CPI 17 - 70µl per lane. The SDS-PAGE was run at 20mA/gel at
20°C for 4.5 hours or 5mA/gel overnight using Hoefer SE600. 10 µl PageRuler prestained protein separation ladder (Thermo Scientific, Rockford, IL) with proteins ranging
from 10kDa to 170kDa was loaded into the first lane.

3. Western blot analysis:
After electrophoresis, western blots were run for the analysis of proteins SMA

	
  
MHC, SMB MHC, total myosin heavy chain, MLCK, MYPT1, PKCα, and PKCδ.
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Gels were equilibrated at room temperature for 1 hour in myosin heavy chain transfer
buffer (25mM Tris HCl, 192mM glycine, 20% methanol, and 0.1% SDS PH 8.3 (Walsh
et al., 2011). Proteins separated by SDS-PAGE then were transferred to nitrocellulose
membrane (0.2µm; Amersham Hybond ECL, GE healthcare, Buckinghamshire, UK) at
200 mA for 4.5 hours at 4°C using Hoefer TE (Hoefer scientific, San Francisco, CA). For
the analysis of proteins β actin, CPI-17, LC20, and phosphorylated LC20, gels were
equilibrated for 30 minutes in myosin light chain transfer buffer (10mM N-cyclohexyl-3aminopropanesulfonic acid (CAPS), pH 11 and 10% methanol), and then transferred to
nitrocellulose at 220 mA for 3 hours at 4°C using GENIE blotter (IDEA scientific,
Minneapolis, MN). After blotting, the nitrocellulose membranes were blocked with 5%
non-fat dry milk in Tris buffered-saline containing Tween 20 (TBST: 20mM Tris HCl,
pH 7.5, 137 mM NaCl, 3mM KCl, and 0.05% Tween 20) for 1 hour at room temperature.
The membrane was then incubated with primary antibodies in 1% non-fat dry milk TBST
for 4 hours. Primary antibody information is shown in Table 1. Membranes were washed
in TBST three times for 5 minutes each and then incubated in the secondary antibodies
for 2 hours. Secondary antibody information are summarized in Table 2. The membranes
were washed three times for 5 minutes each in TBST again. Chromomeric substrate-3.3’diaminobenzidine (DAB) was used to detect proteins. Nitrocellulose membranes were
incubated in developing solution (0.01% H2O2 (v/v), 0.05% DAB (w/v), 0.01M
Imidazole) (Eddinger and Wolf, 1993) for 30 seconds to 2 minutes. The protein bands on
the membranes were scanned by EPSON expression1600 scanner and quantified by
densitometric analysis using the software Image J (http://rsbweb.nih.gov/ij/). To
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Primary antibody

Dilution

Catalogue
Number

Polyclonal rabbit anti PKCα

1:500

sc-208

Polyclonal rabbit anti PKCδ

1:200

sc-213

Polyclonal rabbit anti
MYPT1

1:500

sc-25618

Polyclonal rabbit anti LC20

1:250

sc-15370

Polyclonal goat anti MLCK

1:500

sc-9452

Polyclonal goat anti CPI-17

1:200

sc-30927

Polyclonal rabbit anti SMA
MHC

1:1000

N/A

Eddinger, 2009

Polyclonal rabbit anti SMB
MHC

1:1000

N/A

Eddinger, 2009

1:2000

BT-562

Biomedical Technologies,
Stoughton, MA

1:500

BT-561

Biomedical Technologies,
Stoughton, MA

1:1000

3381

Minipore, Temecula, CA

1:1000

A1978

Sigma, St. Louis, MO

Polyclonal rabbit anti total
myosin chain (SM+NM
MHC)
Polyclonal rabbit anti non
muscle myosin
Polyclonal rabbit anti
phosphorylated LC20 at
Ser19
Monoclonal mouse anti β
actin

Resources
Santa Cruz biotechnology,
Santa Cruz, CA
Santa Cruz biotechnology,
Santa Cruz, CA
Santa Cruz biotechnology,
Santa Cruz, CA
Santa Cruz biotechnology,
Santa Cruz, CA
Santa Cruz biotechnology,
Santa Cruz, CA
Santa Cruz biotechnology,
Santa Cruz, CA

Table 1. Primary antibody information used in western blot.

	
  
Secondary antibody
Goat anti rabbit
IgG-horseradish
peroxidaseconjugated
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Dilution

1: 10,000

Catalogue Number

Resources

111-035-003

Jackson
ImmunoResearch
Laboratoeries, West
Grove, PA

Goat anti mouse
IgG-horseradish
peroxidaseconjugated

1:10,000

115-035-003

Jackson
ImmunoResearch
Laboratoeries, West
Grove, PA

Donkey anti goat
IgG-horseradish
peroxidaseconjugated

1:5,000

HAF109

R&D System,
Minneapolis, MN

Table 2. Secondary antibody information used in western blot.

	
  
minimize variability, tissue samples from a single animal were run in triplicate.
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Densitometric results of the three runs were averaged, and used as an n=1 for data
analysis.
E. Force Measurement:
The mucosa and connective tissues were dissected away from underlying smooth
muscle tissues (fundus, antrum, and ileum). The dissection of tissue strips followed the
protocol of Driska et al (1981). Circular smooth muscle tissues were cut into strips which
were held at each end by tissue clips (PY8 56-5119 Harvard Apparatus, Holliston, MA)
mounted on the two hooks to an isometric force transducer (Harvard Apparatus, Holliston,
MA) and a stationary post for tension measurements. Force signals obtained from force
transducers were processed by an analog to digital converter (PowerLab/8SP,
ADInstruments, Sydney, Australia) and analyzed using Chart5 software (ADInstruments,
Sydney, Australia) on a personal computer. The strip sizes between the two clips were
approximately 3mm in width and 7mm in length. The mounted tissues were bathed in 10
ml glass chambers (Radnoti glass technology, Monrovia, CA) and aerated with 95%
O2/5% CO2 to maintains the bicarbonate buffering system throughout the experiments at
37°C which was maintained by an immersion circulator (VWR, West Chester, PA). The
mounted tissues were equilibrated in PSS for 1 hour at 37°C. By adjusting strip length, a
0.9 g preloaded force was applied for the tissue strip to reach the length for optimal
tension development. Tissue strips were contracted using high potassium containing
physiological saline solution (KPSS: 109.65mM KCl, 1.2mM Na2HPO4, 2.0mM MOPS,
0.02mM EDTA, 1.2mM MgSO4, 5.6mM glucose, 1.6mM CaCl2, 35.1mM NaCl PH 7.4

	
  
at 37°C) for three contraction and relaxation cycles. All subsequent experiments
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included 1µM phentolamine and 0.1µM propranolol to eliminate the potential
neurotransmitter activities. KPSS responsive force traces were obtained in the presence of
KPSS for at least 15 minutes followed by relaxation via PSS washing three times. For
inhibition of secondary messenger pathways, tissue strips were incubated in PSS with
inhibitors (PKCα inhibitors: 1µM GŐ 6976 or GF 109203X; ROCK inhibitors: 10µM
Y27632 or 0.1µM H1152)(EMD chemicals, Gibbstown, NJ) for 30 minutes, and then
stimulated with KPSS for a minimum of 15 minutes followed by three PSS washes to
completely remove inhibitors. At the end of the experiments, KPSS was applied to test
the tissue viability. For phorbol 12,13-dibutyrate (PDBu; EMD chemicals, Gibbstown, NJ)
induced contractile experiments, tissue strips were bathed in PSS with 1µM PDBu, 1µM
phentolamine and 0.1µM propranolol for 30 minutes followed by three PSS washes to
completely remove residual PDBu. Similarly, at the end of the experiments, KPSS was
applied to test the tissue viability. Stress was calculated according to Herlihy et al.
(Herlihy and Murphy, 1973). Briefly, wet weight was measured for each strip. The force
produced per cross sectional area (stress) was calculated as F/A
(mN/cm2)=(m(g)*g)/((wet weight (g)/(Length(cm)*1.05(g/ml))) (g=9.8m/s2 ).

F. Myosin regulatory light chain 20 (LC20) phosphorylation measurements:
A rapid freeze method was used to preserve the phosphorylation status of LC20
(Driska et al., 1981). Tissue strips (approximately 3mm x 7mm) were incubated in PSS
with 1µM phentolamine and 0.1µM propranolol for 1 hour, and then activated with KPSS
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or CCh. Tissue strips were immediately frozen in dry ice-acetone bath (-78°C) before
stimulation or at 30 second, 1 minute, and 10 minute time points after stimulation. The
frozen tissue strips were stored overnight at -78°C and then allowed to gradually warm to
room temperature in acetone. In this process, acetone replaced the water inside smooth
muscle cells, denatured the endogenous phosphatase, kinase and other enzymatic proteins,
and thereby preserved phosphorylation status of LC20 at the time when the tissue strips
were frozen. The dry weights of tissue strips were measured after acetone was thoroughly
evaporated. The wet weights of tissue strips were estimated to be 5 fold greater than the
dry weight (water accounted for 80% of the cell weight) (Hai and Murphy, 1989). Dried
tissue strips were homogenized with sample buffer at 4°C to obtain tissue samples at
10mg/ml dry weight. The homogenates were boiled at 100°C and centrifuged at 13000
rpm for 10 minutes. Supernatant were collected and loaded onto 15% SDS-PAGE at 15µl
per lane (based on protein loading curves showing linearity of signal above and below
this level) for protein separation. The separated proteins were trans blotted to 0.2µl
nitrocellulose membrane, where Ser19 phosphorylated LC20 and LC20 were detected with
specific antibodies indicated above (western blot analysis section of this dissertation).
The LC20 phosphorylation was normalized to β actin and reported as a ratio to total LC20
content for comparison. The arbitrary LC20 phosphorylation values (normalized to LC20)
from densitometric analysis (ImageJ) are only valid for each western blot run, and thus
cannot be compared to other runs.
G. Quantification of tonic contractile components:

The area under the active force trace (total force minus passive force) was

	
  
measured to quantitatively compare the tonic contractile component produced by the
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tissues. With KPSS or CCh stimulation, force developed very quickly to reach the
maximal force levels (peak force), and then gradually decayed to a submaximal level and
remained there until stimuli were removed. To standardize the comparison, the force
values for a specific agonist were normalized to the peak force values in both the wild
type and SMB (-/-) tissues. The normalized active force trace from the peak force to 10minute post peak (force at 10min) was selected and the area under that part of the trace
was calculated by summing up all the force values over the time (Integral calculation).
Additionally, in our case, 10 minutes after KPSS or CCh stimulation, forces decayed to a
steady submaximal level. The ratios of submaximal forces at 10-minute time point to the
peak forces (force at 10min/peak force) from the same active force trace were also
calculated as an alternative method. The area under the active force trace and the force at
10min/peak force were both analyzed to compare tonic contractions.
H. Analysis of force transient:

Time to peak tension (TPT) (from force initiation to peak force), the area under
the active force curve (from force initiation to peak force), and the slope of rapid force
transient (steepest slope during initial force generation, dp/dt) were measured to
quantitatively compare the initial fast force transient induced by KPSS or CCh. The area
under the curve was calculated by summing up all the force values over the time (minutes)
(integral calculation).

	
  
I. Histological analysis:
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Eight-micron thick frozen tissue sections (Leica CM1900) picked up on glass
slides were thawed at room temperature and stained with haematoxylin and eosin to
examine general morphology(Kiernan, 2008). Wall thickness of ileum, antrum and
fundus were measured based on the average of 3 measurements from 4 representative
cross sections using a 40X objective for ileum and fundus and 10X objective for antrum
(Olympus IX70) and IPLab software (Scanalytics, Fairfax, VA).
J. Statistical data analysis:

For comparison of KPSS stimulated tonic contractile force, protein expression,
and LC20 phosphorylation levels between wild type and SMB (-/-) tissues, data were
examined for significant differences using a two-tailed student’s t test with equal variance.
Data was deemed significant at P-value of P<0.05. For comparison of tonic contractile
force with or without inhibitors in SMB (-/-) tissues, one-way ANOVA was used.
Significance was determined as a P value less than 0.05.

	
  
III. Results:
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Ileum and stomach antrum exhibit phasic smooth muscle contractions, and
stomach fundus exhibits tonic smooth muscle contraction (Han et al., 2006, Eddinger et
al., 2001, Eddinger 2009, Rondelli et al., 2007, Smolyo et al., 1968, White et al., 1993).
Thus, this project used longitudinal ileum and circular antrum as representative phasic
smooth muscle tissues and circular fundus as representative tonic smooth muscle tissue to
study the role of the SM SMA/B MHC isoforms in phasic and tonic smooth muscle
contractions (Longitudinal ileum, circular antrum, and circular fundus will be referred to
simply as ileum, antrum, and fundus, respectively).

A. Aim one was to determine if SMB MHC isoform expression is required for
smooth muscle to exhibit phasic contraction.
The SM SMB MHC isoform is preferentially expressed in phasic muscle. To
understand the role of the SM SMB MHC isoform in phasic contraction, an exon-specific
gene targeted SMB knockout approach was used to determine if the SM SMB MHC
isoform is necessary for smooth muscle to exhibit phasic contraction.

1. Generation and characterization of SMB knockout (SMB(-/-)) mice.
a. SMB(-/-) Mice.

SMB(-/-) mice were kindly provided by Dr. Babu and Dr. Periasamy (Babu et al.,
2001). The generation of SMB(-/-) mice has been published (Babu et al. 2001).

	
  
b. SMB(-/-) mice genotype.
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To identify wild type (SMB(+/+)), heterozygous (SMB(+/-)), and knockout (SMB(-/-))
mice, genotyping was carried out. Two primer sets specific for the wild type allele
(Ex5B/MHC 31 which is SMB specific) and mutant allele (PGK/MHC 31 which is
neomycin specific) were used. The DNA electrophoresis results are shown in Figure 4.
SMB(+/-) mice have both the SMB Ex5B and neomycin genes. Therefore, the DNA
fragments amplified by Ex5B/MHC 31 and PGK/MHC 31 respectively were present in
the DNA agarose gel (Figure 4 lane 1 and 2). SMB(+/+) mice do not have the neomycin
gene but do have the SM SMB MHC in their genome. Thus only the DNA fragment of
Ex5B was amplified (Figure 4 lane 3 and 4). Neomycin replaced Ex5B in SMB(-/-) mice
genomes. Thus, only the DNA fragment amplified by PGK/MHC 31 primers was present,
with no fragment amplified by Ex5B/MHC 31 primers in SMB(-/-) mice. (Figure 4 lane 5
and 6). The genotyping identified a SMB(+/+) mouse as having the SMB MHC gene but
not the neomycin gene, a SMB(+/-) mouse with the inserted neomycin cassette has both
the SMB MHC gene and the neomycin cassette, and the SMB(-/-) mouse has the neomycin
gene but not SMB MHC gene.

c. SM SMB MHC protein expression in SMB(+/+) and SMB(-/-) mice.

To verify that the insertion of the neomycin cassette took the place of Exon 5B of
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Figure 4. DNA electrophoresis gel results loaded with PCR products from SMB(+/+),
SMB(+/-), and SMB(-/-) mice. The fragment of Ex5B (245bps) was amplified in the
SMB(+/+) mouse. Both the fragments of Ex5B and the PGK neomycin were amplified in
the SMB(+/-) mouse. The fragment of PGK neomycin (219 bps) was amplified in the
SMB(-/-). From left to right: Lane 1-2: Amplified SMB(+/+) mouse genome. Lane 3-4:
Amplified SMB(+/+ ) mouse genome. Lane 5-6: Amplified SMB(-/-) mouse genome (Lane
1,3,5: amplified by Ex5B primers (SMB MHC). Lane 2,4,6: amplified by neomycin
primers (Neo)).
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(-/-)
SMB MHC and knocked down SMB MHC expression at protein level in SMB mice,
western blotting was conducted using an anti-SMB serum (Eddinger, 2009). If SM SMB
MHC isoform is knocked down in SMB(-/-) mice, the expression of SMB MHC protein
will be significantly decreased compared to SMB(+/+).

The proper sample loading volume for SMB MHC quantification on western blot
was determined by standard western blot sample-loading curve. Figure 5 shows the
representative standard sample-loading curve for β actin (which was used to normalize
protein loadings between samples)(Figure 5A) and SMB MHC (Figure 5B). The standard
curve typically has a linear portion where the western blot signal is positively correlated
with the increasing sampling loading volume. Sample loadings within this range of the
curve can be quantified by western blot. Table 3 shows standard sample loading ranges
for western blot for various proteins tested in this dissertation. The squared correlation
coefficient ranged from 0.94 to 0.99 (R2=0.94~0.99). To minimize variability, tissue
samples from a single animal were run in triplicate. Figure 6 shows western blot example
of triplicate loading of phosphorylated LC20 of SMB(+/+) and SMB(-/-) fundus.

Quantified western blot analysis results of SMB MHC expression in SMB(+/+) and
SMB(-/-) ileum, antrum, and fundus are shown in Table 4. Expression of SMB MHC
protein was significantly decreased in SMB(-/-) ileum and antrum compared to SMB(+/+),
consistent with the neomycin cassette replacing the Exon 5B and this exon- Additionally,
western blot results using SMA MHC specific antibody (Eddinger, 2009) targeting
expression of SMA MHC was significantly increased in SMB(-/-) ileum and
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50 µl
70µl
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110µl 130µl
Figure 5. The representative western blot result of standard sample loading
curve for SMB(-/-) ileum β actin (loading control) and SMB(-/-) ileum SMB MHC protein.
Upper graph: 50mg/ml SMB(-/-) ileum was loaded from 5µl to 35µl with 5µl increment for
β actin quantification using β actin specific antibody. From 5µl to 25µl, the loading
volume and western blot signal strength shows a linear relationship. (R2=0.99). Beyond
30µl, the western blot signal strength was saturated. Based on these data, the loading
range used for data analysis was between 15µl and 25µl. Lower graph: The standard
sample loading curve for SMB MHC protein of SMB(-/-) ileum. The linear range for
SMB(-/-) ileum SMB MHC was from 50 µl to 90 µl with R2=0.97, and loadings for data
analysis for SMB MHC was from 50 µl to 90 µl.

	
  
Tissue

Protein

Type
SMB(+/+)
ileum

SMB(-/-)
ileum

SMB(+/+)
antrum

SMB(-/-)

SMB MHC
SMA MHC
Total myosin
MLCK
MLCP
PKCδ
PKCα
β actin
Phosphorylated
LC20
LC20
CPI-17
SMB MHC
SMA MHC
Total myosin
MLCK
MLCP
PKCδ
PKCα
β actin
Phosphorylated
LC20
LC20
CPI-17
SMB MHC
SMA MHC
Total myosin
MLCK
MLCP
PKCδ
PKCα
β actin
Phosphorylated
LC20
LC20
CPI-17
SMB MHC
SMA MHC

2
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Loading volume
range determined
from linear part of
standard loading
curve (µl).
30-70
40-80
30-75
10-50
5-40
30-40
10-30
10-50
10-30

Loading volume R value for
used for western linear part of
blot analysis (µl). standard
loading curve
50
50
50
30
30
30
15
15
15

0.98
0.96
0.99
0.96
0.97
0.96
0.99
0.96
0.99

10-30
70-90
50-90
30-60
30-70
10-45
15-55
30-40
10-50
5-25
10-30

15
70
50
50
50
30
30
30
15
15
15

0.99
0.95
0.97
0.97
0.98
0.99
0.98
0.96
0.98
0.99
0.99

10-30
70-95
5-20
25-35
5-35
5-35
5-40
30-40
5-15
10-60
10-30

15
70
15
30
15
30
30
30
15
15
15

0.99
0.96
0.98
0.98
0.95
0.98
0.99
0.95
0.99
0.99
0.99

10-30
70-90
5-25
5-35

15
70
15
15

0.99
0.95
0.94
0.99

	
  
antrum

SMB(+/+)
fundus

SMB(-/-)
fundus
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Total myosin
MLCK
MLCP
PKCδ
PKCα
β actin
Phosphorylated
LC20
LC20
CPI-17
SMB MHC
SMA MHC
Total myosin
MLCK
MLCP
PKCδ
PKCα
β actin
Phosphorylated
LC20
LC20
CPI-17
SMB MHC
SMA MHC
Total myosin
MLCK
MLCP
PKCδ
PKCα
β actin
Phosphorylated
LC20
LC20
CPI-17

15-35
10-30
5-40
30-40
5-20
10-25
10-30

20
30
30
30
15
15
15

0.99
0.99
0.98
0.99
0.99
0.97
0.99

10-30
70-90
5-25
5-35
5-30
15-30
10-35
30-40
10-30
5-30
5-30

15
70
15
15
15
30
30
30
15
15
15

0.98
0.96
0.99
0.98
0.99
0.98
0.98
0.96
0.98
0.99
0.99

5-35
65-70
5-25
5-35
5-30
5-30
5-40
30-40
5-20
4-18
10-30

15
70
15
15
15
30
30
30
15
15
15

0.98
0.96
0.95
0.97
0.99
0.99
0.97
0.95
0.99

10-30
65-75

15
70

0.97
0.96

0.97

Table 3. Western blot sample loading volumes for various smooth muscle contraction
regulatory proteins. The loading volume ranges determined from linear part of standard
curves in the table were obtained based on the standard curve specific to each of the
corresponding protein. β actin was used as loading control.
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  SMB(+/+)	
  	
  SMB(-‐/-‐)	
  SMB(+/+)	
  SMB(-‐/-‐)	
  SMB(+/+)	
  SMB(+/+)	
  
Phosphorylated	
  LC20	
  
	
  
β	
  actin	
  

Figure 6. Western blot example of triplet loading. Western blot result of phosphorylated
LC20 in SMB(+/+) and SMB(-/-) fundus (top) and the β actin loading control (bottom). 30µl
50mg/ml SMB(+/+) and SMB(-/-) fundus samples from one SMB(+/+) and one SMB(-/-)
mouse were loaded in triplicate pairs. The quantified densitometric result from each of
the pair were averaged as the n=1 for phosphorylated LC20 in SMB(+/+) and SMB(-/-)
fundus.
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strategy effectively reducing SMB MHC gene expression (Table 4) showed that the
antrum compared to SMB(+/+) (Table 4). Because the SMB MHC is expressed at very
low/undetectable levels in the SMB(+/+) fundus , the loss of SMB MHC in the SMB(-/-)
fundus did not show a significant decrease in SMB MHC or increase in SMA MHC
expression compared to SMB(+/+) fundus tissues. Results of western blot using total
myosin antibody (SM+NM) ((Cat # BT-562 Biomedical Technologies, Stoughton, MA)
indicated that the expressions of total myosin (including both the SMA/B SM MHC and
NM MHC) were unaltered in all three tissues (Table 4). The expression of NM MHC was
not altered in SMB(-/-) ileum (Table 4). Loss of SMB MHC protein resulted in a
compensatory switching from the SMB MHC isoform to the SMA MHC isoform such
that neither NM MHC nor total MHC expression was altered.

d. Gross histological organization of SMB(+/+) and SMB(-/-) tissues.

To determine any gross histological alteration in SMB(-/-) animals, ileum, antrum,
and fundus tissues were frozen, sectioned and stained with haematoxylin and eosin.
Figure 7 shows representative histologic micrographs of haematoxylin and eosin stained
cross sections of SMB(+/+) and SMB(-/-) ileum, antrum, and fundus. The width (µm) of the
smooth muscle layer of SMB(-/-) tissues was similar to their matched WT tissues ( Ileum:
36.9±3.51 (WT), 42.13±7.44 (KO); Antrum: 549.02±42.68 (WT), 524.73±49.23 (KO);
Fundus: 82.38±20.75 (WT), 69.89±11.72 (KO); n=3-4). No gross histological differences
were observed in these tissues between SMB(-/-) and SMB(+/+) animals.
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Tissue
type

Ileum

Antrum

Fundus

Protein

SMB(+/+)**

SMB(-/)
**

P value

Representative western
blot results
SMB(+/+) SMB(-/-)

4.059E6*
2.442E5*

SMB MHC

1.17±0.03

0.03±0.01

SMA MHC

0.46±0.02

1.64±0.05

Total
myosin

1.12±0.13

1.13±0.15

0.36

NM myosin

0.98±0.05

1.19±0.08

0.092

SMB MHC

0.84±0.06

0.13±0.06

0.0001*

SMA MHC

0.71±0.15

1.59±0.14

0.012*

Total
myosin

1.59±0.31

1.66±0.4

0.884

SMB MHC

0.71±0.11

0.81±0.04

0.454

SMA MHC

1.00±0.04

1.01±0.04

0.886

Total
myosin

1.02±0.08

0.99±0.08

0.832

β actin
β actin
β actin
β actin
β actin
β actin
β actin
β actin
β actin
β actin

Table 4. Quantitative western blot results of the expression of SMB and SMA MHC and
total myosin in SMB(+/+) and SMB(-/-) ileum (including NM myosin), antrum and fundus
with β actin as loading control. The expressions of SMB and SMA MHCs were
significantly decreased and increased in SMB(-/-) ileum and antrum respectively compared
to SMB(+/+). No significant change of SMB expression was observed in SMB(-/-) fundus.
The expressions of total myosin (SM+NM) and NM myosin were not significantly
different between SMB(+/+) and SMB(-/-) ileum, antrum, fundus.
Values are mean ± SE. ** Arbitrary densitometric units. * Difference determined by ttest to be significant at P<0.05. n=3 for all groups.
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SMB

Ileum

Fundus

Antrum

Figure 7. Transverse H&E section through SMB(+/+) (left) and SMB(-/-) (right) ileum
(upper panels), fundus (middle panels), and antrum (lower panels). There are no obvious
gross differences between the SMB(+/+) and SMB(-/-) tissues. M: mucosa, muscularis
mucosa, and submucosa. CM: circular smooth muscle layer. LM: longitudinal smooth
muscle layer. Scale bar equals 20µm (ileum and fundus) or 200µm (antrum).

	
  
2. Phasic contractions in SMB(+/+) and SMB(-/-) phasic smooth muscle tissues.
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The preferential expression of the SM SMB MHC isoform in phasic tissue, and its
greater ATPase activity relative to the SMA MHC isoform suggest that SMB MHC may
play an important role in regulating phasic contraction. To determine whether the SMB
MHC is involved in phasic contraction, SMB(-/-) phasic tissues (ileum and antrum) were
stimulated by depolarization (KPSS) or physiological agonist analog (Carbachol (CCh)).
If a phasic contraction requires SMB MHC expression, the phasic contractile pattern of
SMB(-/-) ileum and antrum will no longer be maintained. Tonic fundus was used as
control.

a. Phasic contraction induced by KPSS in SMB(+/+) and SMB(-/-) ileum and antrum.
KPSS, a physiological saline solution with 109.6mM K+ substituted for Na+,
depolarizes muscle to induce contraction. To compare the phasic component of
contraction between SMB(+/+) and SMB(-/-) mice, isometric force traces with KPSS
stimulation were recorded. The phasic and tonic components of an isometric force trace
are shown in Figure 8. The isometric- recorded force trace consists of an initial fast force
transition after activation, which is the phasic component of a contraction (enclosed
dotted region). After force reaches maximum level, the maintenance of force occurs via
the tonic component of the contraction (enclosed solid region). Figure 9 shows
representative isometric force traces for SMB(-/-) and SMB(+/+) ileum,
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Tonic	
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Figure 8. Representative force trace showing the phasic and tonic components of an
isometric contraction. The force trace included in dotted region is the phasic component
of the contraction. The force trace enclosed with a solid region is the tonic component of
the contraction.
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Figure 9. Representative KPSS isometric force traces of SMB(+/+) and SMB(-/-) ileum,
antrum, and fundus. In order to compare the contraction patterns between SMB(+/+) and
SMB(-/-) smooth muscle tissues, active peak forces were normalized to 1. Isometric force
traces for SMB(+/+) and SMB(-/-) ileum (upper panel), SMB(+/+) and SMB(-/-) antrum
(middle panel), and SMB(+/+) and SMB(-/-) fundus (lower panel). In both the ileum and
antrum the tonic force component is significantly increased in the SMB(-/-) animals
relative to the SMB(+/+).

	
  
antrum, and fundus induced by KPSS. As shown in Figure 9, a rapid force transition
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induced with KPSS is still present in SMB(-/-) ileum, antrum and fundus compared to
SMB(+/+), suggesting that phasic contraction does not require the SMB MHC. Further
analysis of the force transition rate of this phasic contraction revealed that the rate of the
force transient for the SMB(-/-) ileum and antrum were significantly slower than the
SMB(+/+) tissues. In contrast, there was no difference for the fundus tissue under the same
condition. To quantitatively compare the force transition rate for ileum, antrum, and
fundus between SMB(+/+) and SMB(-/-), three measurements (the time taken to reach the
peak force, slope of the linear part of force transient (Figure 10) and the area under the
active force curve from force initiation to peak force (Figure 11)) were carried out for
calculating the phasic isometric force induced by KPSS. The area under the active force
curve from force initiation to peak force is indicated in Figure 11. Results of three
measurements are summarized in Table 5. The time taken from force initiation to peak
force and the area under the active force curve from force initiation to peak force were
significantly increased, and the slope of the linear force transient was significantly
decreased in SMB(-/-) ileum and antrum compared to SMB(+/+). These results suggest that
there is a decreased force transient rate in SMB(-/-) verses SMB(+/+) ileum and antrum
when activated with KPSS. The fundus control showed no change between the SMB(+/+)
and SMB(-/-) tissues.
Thus, in the SMB (-/-) ileum and antrum, stimulated by KPSS, loss of SMB MHC
isoform results in a phasic contraction with unaltered maximal tension but a slower force
transition rate.
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Figure 10. Expanded view of initial isometric force traces activated by KPSS (left) or
5µM CCh (right). Ileum (upper panels), antrum (middle panels), and fundus (lower
panels). Force transition rate was significantly slower in SMB(-/-) ileum and antrum than
SMB(+/+), but not for the fundus. X-axis indicates the time (in second) after force
initiation
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Figure 11. Measurements used to quantitatively compare force transition rate, and tonic
contractile component between SMB(+/+) and SMB(-/-). Dotted arrow pointed area was the
area under the active force curve from force initiation to peak force, which was used to
compare force transient rate. The area under the active force curve (enclose by dotted line)
(from peak force (solid arrow) to 10 minutes (solid arrow head) after peak force) and the
10minute force/peak force ratio were used for tonic contractile comparison.
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Treatment

Tissue

SMB(+/+)
SMB(-/-)
P value
SMB(+/+)
Antrum
SMB(-/-)
P value
SMB(+/+)
Fundus
SMB(-/-)
P value
SMB(+/+)
Ileum
SMB(-/-)
P value
SMB(+/+)
Antrum
SMB(-/-)
P value
SMB(+/+)
Fundus
SMB(-/-)
P value
Ileum

KPSS

CCh

n

Slope of
linear
ascending
force
(g/s)

11 0.8±0.14
12 0.31±0.04
0.002*
7 1.16±0.23
7 0.54±0.1
0.029*
12 1.07±0.23
14 0.66±0.14
0.123
5 0.35±0.13
8 0.09±0.02
0.029*
6 0.61±0.07
5 0.24±0.06
0.006*
6 0.47±0.08
7 0.35±0.09
0.3

n

Time to
peak
tension
(min)

n

11 0.19±0.03 11
11 0.32±0.04 11
0.012*
12 0.09±0.01 12
12 0.24±0.04 12
0.001*
12 0.29±0.02 12
13 0.41±0.06 13
0.091
13 0.44±0.01 13
13 0.51±0.01 13
0.04*
12 0.47±0.02 12
12 0.74±0.05 12
0.01*
7 0.48±0.07 7
7 0.56±0.12 7
0.581

Area
under the
curve
(Force
initiation
to peak
force)
0.13±0.02
0.21±0.03
0.009*
0.05±0.01
0.1±0.02
0.02*
0.2±0.06
0.2±0.02
0.996
0.21±0.04
0.43±0.03
0.02*
0.32±0,02
0.48±0.01
0.02*
0.42±0.1
0.45±.05
0.732

Table 5. Force transient comparison for SMB(+/+) and SMB(-/-) ileum, antrum, and fundus
with KPSS or 5µM CCh stimulation. With KPSS stimulation, the force developmental
time to reach the peak force and the force initiation to peak force area under the active
force curve significantly increased and the slope of linear ascending force is decreased in
SMB(-/-) ileum and antrum, indicating a decreased force developmental rate in these
SMB(-/-) smooth muscle tissue contraction.
Values are mean ± SE. * Difference determined by t-test to be significant at P<0.05.
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(+/+)
b. Phasic component of contraction induced by Carbachol (CCh) in SMB
and
SMB(-/-) antrum and ileum.
Acetylcholine (ACh) has been reported to be the major excitatory
neurotransmitter released from the enteric nervous system causing gut motility (Bornstein
et al., 2004; Furness et al., 1995; Furness, 2012; Murthy, 2006). For our studies, we used
an ACh analog (CCh) which is not hydrolysable by the acetylcholine esterase to
determine whether the same results with KPSS stimulation will be observed with more
physiological stimulati. The maximum stress values are not different between CCh
activated SMB(+/+) and SMB(-/-) ileum, antrum and fundus ( mN/cm2; ileum: 17.4±2.4
(WT), 22.9±3.6 (KO); antrum: 7.5±2.2 (WT), 13.2±4.3 (KO); fundus: 20.2±3.3 (WT),
20.3±4.0 (KO). n=4~7, P>0.05).
Representative force traces vs. time with 5µM CCh stimulation are shown in
Figure 12. The estimates of the rate of phasic contraction were measured in SMB(+/+) and
SMB(-/-) ileum, antrum, and fundus. Results are shown in Table 5. Similar to KPSS
stimulation, CCh induced contractions in SMB(-/-) ileum and antrum had a phasic
component with increased time to peak force and area under the active force curve from
force initiation to peak force, and decreased slope of force transient relative to the
SMB(+/+) tissues. No difference appeared in fundus tissues tested.

c. LC20 phosphorylation in SMB(+/+) and SMB(-/-) tissues.

To determine whether the deceased force transient in SMB(-/-) ileum and antrum
was caused by the protein expression switch from “fast” SMB MHC to
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Figure 12. Representative isometric force traces of SMB(+/+) and SMB(-/-) ileum, antrum,
and fundus stimulated by 5µM CCh. In order to compare the contraction patterns between
SMB(+/+) and SMB(-/-) smooth muscle tissues, active peak forces were normalized to 1.
“slow” SMA MHC isoform, LC20 phosphorylation status at 5 seconds (rapid phasic force
transient) was measured. The phosphorylation status of LC20 was not significantly

	
  
different between SMB(+/+) and SMB(-/-) in ileum and antrum at 5 second time point
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(Table 6), which suggested that LC20 phosphorylation (5 seconds) is not different during
the force transient to the maximal force between SMB(+/+) and SMB(-/-) , thus the
difference in mechanical response is not due to the differences in LC20 phosphorylation
levels. Similarly, no significant difference of LC20 phosphorylation was observed in
SMB(+/+) and SMB(-/-) fundus at this time point (Table 6).
Results of isometric force measurement with either KPSS or CCh in SMB(-/-)
ileum and antrum exhibited a phasic component of contraction with increased time to
peak and area under the active force curve from force initiation to peak force, and a
decreased force transient slope, which suggested a slower force transient rate in these
tissues.

B. Aim two was to investigate if the SMA MHC isoform expression alone is able to
display a tonic contraction in a phasic tissue where the SMB MHC is originally
predominantly expressed.

In the previous section, results indicated that SM SMB MHC was not required for phasic
contraction but affected the force transient of the phasic contraction. However, the
correlation between predominant expression of SMA MHC isoform in tonic tissues and
tonic contraction remains unresolved. To address this, isometric force traces were
compared between SMB(+/+)and SMB(-/-) ileum, antrum and fundus strips. If SMA MHC
isoform is responsible for tonic contraction, loss of SMB MHC protein expression with

Phosphorylation

SMB(+/+)

SMB(-/-)

P value

Representative

	
  

63	
  
time point

western blot result
SMB(+/+) SMB(-/-)
Ileum

LC20-Pi at 5
sec **

0.88±0.09 1.08±0.09

0.188

LC20-Pi at 1
min **

0.89±0.2

1.15±0.21

0.425

LC20-Pi at 10
min **

1.15±0.09 1.14±0.09

0.93

Pi-LC20
LC20
β actin
Pi-LC20
LC20
β actin
Pi-LC20
LC20
β actin

Antrum
LC20-Pi at 5
sec **

0.95±0.14 1.03±0.22

0.786

LC20-Pi at 1
min **

0.89±0.28 1.18±0.15

0.415

LC20-Pi at 10
min**

0.95±0.06 1.02±0.08

0.644

Pi-LC20
LC20
β actin
Pi-LC20
LC20
β actin
Pi-LC20
LC20
β actin

Fundus
LC20-Pi at 5
sec **

1.04±0.07 0.99±0.06

0.565

LC20-Pi at 1
min **

1.02±0.22 0.93±0.09

0.737

LC20-Pi at 10
min **

1.01±0.1

0.363

1.13±0.07

Pi-LC20
LC20
β actin
Pi-LC20
LC20
β actin
Pi-LC20
LC20
β actin

Table 6. LC20 Phosphorylation status at 5 seconds, 1minute, and 10 minutes time points
in KPSS stimulation. There are no significant difference in LC20 Phosphorylation status
at 5 seconds, 1minute, or10 minutes time points in KPSS stimulation between SMB(+/+)
and SMB(-/-) tissues. ** Arbitrary densitometric units. Values are mean of percent
phosphorylated LC20 (of total SMB(+/+) and SMB(-/-) samples) divided by percent total
LC20 (of total SMB(+/+) and SMB(-/-) samples) after each was corrected for loading (β actin)
± SE. * Difference determined by t-test to be significant at P<0.05. n=3 for all groups.

	
  
an increased SMA MHC protein expression should make SMB(-/-) phasic smooth
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muscle exhibit a strong tonic contraction.
1. Tonic contractions in SMB(+/+) and SMB(-/-) phasic smooth muscle tissues.

a. Tonic contraction induced by KPSS in SMB(+/+) and SMB(-/-) ileum and antrum.
The isometric force trace with KPSS stimulation examined in the previous section not
only had a phasic component but also a tonic component (Figure 9). As shown in Figure
9, after force reached the peak force, it began to decrease. However, forces in SMB(-/-)
ileum and antrum did not decrease to the same level as SMB(+/+) tissues, instead they
were maintained at a intermediate force level which was higher than the tonic forces in
these tissues for SMB(+/+) animals. There were no differences in the tonic forces from
SMB(+/+) and SMB(-/-) fundus tissues. To quantitatively compare the tonic component of
contraction stimulated with KPSS between SMB(+/+) and SMB(-/-) ileum and antrum, the
active peak force from both SMB(+/+) and SMB(-/-) tissues were normalized to 1, and then
the area under the active force curve were measured from peak force to 10 minutes after
peak force as the indicator of the tonic component (Figure 11). An alternative way to
measure the tonic contractile component was the 10 minute force (steady state) (Figure
11). Results from these measurements are summarized in Table 7. The area under the
active force curve (peak force to 10 minutes after peak) was significantly larger in SMB(/-)

ileum and antrum compared to SMB(+/+). 10 minute KPSS force was also greater in

SMB(-/-) than SMB(+/+) animals. The results from both of the measurements indicated that
with KPSS stimulation SMB(-/-) ileum and antrum were more tonic than SMB(+/+).
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Tissue
SMB(+/+)
SMB(-/-)
P value
Antrum SMB(+/+)
SMB(-/-)
P value
Fundus SMB(+/+)
SMB(-/-)
P value
Ileum

n
13
13
7
7
11
11

Area under the curve**
4.03±0.36
5.47±0.35
0.017*
2.73±0.24
3.81±0.21
0.005*
5.85±0.54
5.84±0.47
0.991

10 min force**
0.37±0.03
0.48±0.04
0.044*
0.19±0.02
0.27±0.03
0.027*
0.47±0.06
0.49±0.06
0.818

Table 7. Quantification of tonic phase activated by KPSS. The tonic component of
contraction was quantified by measuring area under force trace from the peak force to 10
minutes after (steady state) and 10 minute force. Increased values for area under force
trace or 10 minute force suggested a larger tonic component. KPSS stimulation was more
tonic in SMB(-/-) ileum and antrum. In KPSS stimulated fundus, the tonic components
between SMB(+/+) and SMB(-/-) were comparable (control). The increased tonic
contractions in SMB(-/- )ileum and antrum may be caused by up regulated SMA MHC.
**Area under the curve was measured from peak force to 10 minutes after peak force. 10
min force is the 10 minute tonic force normalized to peak force.
Values are mean ± SE. * Significant at P< 0.05.
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(+/+)
(-/-)
b. Tonic contraction induced by CCh in SMB
and SMB ileum and antrum

To determine whether switching from SMB MHC expression to SMA MHC
expression could also result in increased tonic force via altered agonist stimulation,
SMB(+/+) and SMB(-/-) antrum, ileum and fundus strips were activated with 5µM CCh. The
tonic component of the isometric force traces of ileum, antrum, and fundus in Figure 12
were quantified and compared between SMB(+/+) and SMB(-/-) using the same
measurements mentioned above. The results of the area under the curve and 10 minute
force are displayed in Table 8, showing that neither area under the curve (peak force to
10 minutes) nor 10 minute force (steady state) changed significantly between SMB(+/+)
and SMB(-/-) except for the ileum. The area under the curve measurement was increased
while the 10 minute force measurement was not in the SMB(-/-) ileum (Table 8). The
results of the two measurements indicated that with CCh stimulation the tonic component
of contraction does not increase in SMB(-/-) antrum. However, the area under the curve
measurement showed that the tonic component of contraction in SMB(-/-) ileum increased
while 10 minute force measurement indicated no change (Table 8). Unlike KPSS
stimulation, CCh activation includes spontaneous contractions of gastrointestinal smooth
muscle as shown in Figure 12 (Ehlert et al., 1999; Sinn et al., 2010; Unno et al., 2006),
which may confound the area under the curve measurement. To test this, the spontaneous
contraction induced by CCh was compared between SMB(+/+) and SMB(-/-) by comparing
spike number and average amplitude from the time of peak force to 10 minutes after. No
significant difference was observed (Table 9).
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Tissue
SMB(+/+)
Ileum
SMB(-/-)
P value
SMB(+/+)
Antrum
SMB(-/-)
P value
SMB(+/+)
Fundus
SMB(-/-)
P value

Area under the curve**
4.15±0.47
5.84±0.18
0.007*
3.72±1.12
2.29±0.31
0.179
5.49±0.27
6.21±0.36
0.160

10 min force**
0.58±0.06
0.57±0.04
0.91
0.21±0.09
0.072±0.01
0.092
0.52±0.03
0.53±0.04
0.844

Table 8. Quantification of tonic phase activated by 5µM CCh. The tonic component of
contraction was quantified by measuring area under the curve from peak force to 10
minute and 10 minute force/peak force (steady state). Increased values for those two
measurements suggest a larger tonic component. CCh stimulated SMB(-/-) ileum, antrum
and fundus were not more tonic than SMB(+/+) by 10 minute force/peak force
measurement. However the area under the curve from peak force to 10 minute was
significantly larger for SMB(-/-) ileum compared to SMB(+/+), indicating SMB(-/-) ileum
was more tonic.
**Area under the curve was measured from peak force to 10 minutes after peak force. 10
min force is the 10 minute tonic force normalized to peak force.
Values are mean ± SE. * Significant at P< 0.05. n=6 for all groups.
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5µM CCh
Ileum
Antrum

(+/+)

(-/-)

Measurement

SMB

n

SMB

Amplitude (g)

0.29±0.06

5

4

0.145

Spike number

22.4±8.74

5 42.75±9.46 4

0.16

Amplitude (g)

0.87±0.21

6

6

0.361

Spike number 15.67±3.16 6 15.57±2.36 6

0.98

0.49±0.12
1.35±0.45

n P value

Table 9. Comparison of spontaneous contraction induced by 5µM CCh between SMB(+/+)
and SMB(-/-) ileum and antrum.
Values are mean ± SE. * Difference determined by t-test to be significant at P<0.05.

	
  
2. LC20 phosphorylation levels with KPSS contraction.
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As mentioned in the introduction, the “latch state” refers to the tonic contraction
in which LC20 phosphorylation is not proportional with sustained force maintenance. In
the “latch state” the LC20 phosphorylation level is low but force can be maintained at a
high level. The loss of SMB MHC results in compensatory upregulated SMA MHC. It
also may result in other alterations in smooth muscle by compensatory mechanisms.
Other alterations that contribute to altered smooth muscle contractile pattern may include
the change in the sensitivity of LC20 phosphorylation to KPSS stimulation, which could
be regulated by serial second messenger pathways or by unknown mechanisms. Thus
whether the increased tonic contraction induced by KPSS in SMB(-/-) antrum and ileum is
caused by elevated LC20 phosphorylation level needs to be addressed before we conclude
that SMA MHC is responsible for tonic contraction.
The phosphorylation status of LC20 in ileum and antrum strips was determined at
1 minute and 10 minutes following KPSS activation. 1 minute was chosen to represent
the time in the force trace showing the largest change in force between SMB(+/+) and
SMB(-/-) animals. 10 minute in KPSS represents steady state. To verify the validity of
phosphorylation measurements, stomach tissues before KPSS stimulation (unstimulated
state should have very little or low level of LC20phosphorylation) and 30 second in KPSS
(peak force when the LC20 phosphorylation should be significantly higher than rest state)
were analyzed. Western blot results using antibodies specific to quantify phosphorylated
LC20 showed that the phosphorylation level of LC20 was significantly higher following 30
seconds in KPSS than before KPSS stimulation (Table 10). Therefore, this method can be
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Protein

Phosphoryl
ated LC20

Phosphorylatio
Phosphorylatio
n of LC20
n of LC20 with
before KPSS
30s KPSS
stimulation** n stimulation**
0.55±0.03
3
1.32±0.26

P
value
n
3 0.04*

Representive western
blot result
Before 30s
KPSS
KPSS
β actin

LC20

1.11±0.13

3

1.09±0.05

3

0.9

Phosphoryl
ated
LC20/LC20

0.51±0.04

3

1.21±0.21

3 0.032
*

β actin

Table 10. Phosphorylation method positive control. The phosphorylation level of LC20 at
30 seconds in KPSS stimulation was significant higher than before KPSS stimulation,
demonstrating that the dry ice acetone method was able to preserve phosphorylation
status.
** Arbitrary densitometric units
* Difference determined by t-test to be significant at P<0.05
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(+/+)
(-/-)
used to compare the LC20 phosphorylation status between SMB
and SMB ileum,
antrum and fundus (control) at 1minute and 10minute KPSS. The results of LC20
phosphorylation status at 1 minute and 10 minute in KPSS are shown in Table 6. The
phosphorylation status of LC20 was not significantly different between SMB(+/+)and
SMB(-/-) ileum and antrum at either the 1 minute or 10 minute KPSS time points
suggesting that the increased tonic contraction in SMB(-/-) ileum and antrum is not due to
the LC20 phosphorylation.
C. Aim three was to examine if the changes in PKC/CPI-17 or Rho/ROCK pathways
are involved in changes in tonic and phasic contractions.

The previous section showed that KPSS stimulation resulted in increased tonic
contraction in SMB(-/-) ileum and antrum, which was not attributed to the alteration of
LC20 phosphorylation status. As discussed in the introduction, second messenger
pathways PKC/CPI-17 and Rho/ROCK may contribute to the “latch state”. Whether the
increased tonic contraction is caused by changes in these signaling pathways needs to be
investigated.
1. Second messenger pathways in tonic contraction induced by KPSS in SMB(+/+)
and SMB(-/-) ileum and antrum.
Two signaling pathways (PKC/CPI-17 and Rho/ROCK) are reported regulate
tonic contraction. Inhibitors reported to specifically inhibit these two signaling pathways
were used to determine whether changes in the KPSS induced tonic contraction in SMB(/-)

ileum and antrum was caused by these specific second messenger pathways.
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a. PKC/CPI-17 signaling pathway in tonic contraction with KPSS stimulation in
SMB(+/+) and SMB(-/-) ileum and antrum.
i. PKC inhibitors in tonic contraction in SMB(+/+) and SMB(-/-) ileum and antrum.
To determine if the PKC/CPI-17 signaling pathway is involved in increased tonic
contraction in SMB(-/-) ileum and antrum, PKC inhibitors Gõ6976 (inhibiting
conventional PKC isoforms) and GF109203X (inhibiting both the conventional and novel
isoforms of PKC) were used in KPSS induced isometric force measurement experiments.
The peak force (area under the active force curve from peak force to 10 minutes) and 10
minute force (steady state) were measured with or without inhibitors (Gõ6976 1µM,
GF109203X 1µM) with KPSS stimulation in SMB(-/-) ileum and antrum. Results are
shown in Table 11. Use of the PKC inhibitors Gõ6976 and GF109203X failed to alter the
increased tonic component of contraction induced by KPSS in SMB(-/-) ileum and antrum,
suggesting that PKC/CPI-17 pathway is not involved in increased tonic contraction in
these tissues.
ii.PKC activation with phorbol ester (PDBu)
If KPSS induced increased tonic contraction in SMB(-/-) ileum and antrum is
mediated by the PKC/CPI-17 signaling pathway, the one would predict directly activating
PKC would have the same result. Phorbol ester (PDBu) is able to mimic the activity of
DAG, which is the activator of PKC. Isometric force measurement were analyzed
following stimulation with 1µM PDBu in SMB(+/+) and SMB(-/-) ileum and antrum strips.
Figure 13 shows representative superimposed force traces for SMB(+/+) and SMB(-/-) ileum
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Tissue
Ileum
SMB(-/-)
Antrum
SMB(-/-)
Tissue
Ileum
SMB(-/-)

Antrum
SMB(-/-)

Measurements
Area under the
curve**
10 min force (g)
Area under the
curve**
10 min force
(g)
Measurements
Area under the
curve**
10 min force (g)
Area under the
curve**
10 min force
(g)

n

Control

Gő6976

GF109203X

13 5.32±0.35 5.55±0.33 5.0573±0.56
8

0.73±0.11 0.59±0.11

0.51±0.12

8

3.87±0.21 4.31±0.46

4.59±0.26

8

1.28±0.39 1.73±0.48

1.78±0.38

n

Control

Y27632

H1152

8

5.32±0.35 4.66±0.58

4.66±0.58

5

0.83±0.21 0.69±0.12

0.74±0.15

7

3.92±0.21 5.51±0.54

4.99±0.87

5

2.05±0.72

2.24±1.1

2.5±1.1

Table 11. Effects of PKC inhibitors (Gő6976 (1µM), GF109203X (1 µM)) and ROCK
inhibitors (Y27632 (10µM), H1152 (0.1µM)). There was no significant difference in
KPSS induced tonic component between SMB (-/-) ileum, antrum and fundus with
inhibitors (either PKC inhibitors or ROCK inhibitors) and control (without any of the
inhibitors).
**Area under the curve was measured from peak force to 10 minutes after peak force.
Values are mean ± SE. *Difference determined by ANOVA to be significant at P<0.05.
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Figure 13. Representative comparison of 1µM PDBu and KPSS isometric force traces of
SMB(+/+) and SMB(-/-) ileum and antrum. Force KPSS active peak force is normalized to 1.
KPSS tonic force is significantly greater in the KPSS tonic phase of the SMB(-/-) tissues
vs. the SMB(+/+). There is no significant difference between the force responses of the
SMB(+/+) and SMB(-/-) tissues in response to PDBu
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and antrum contractions induced by 1µM PDBu in comparison to the KPSS responses.
The forces induced by PDBu in both the SMB(+/+) and SMB(-/-) tissues were very small
(less than 0.6g compared to ~3 and 6 grams peak force with KPSS for ileum and antrum
respectively) and barely above zero for the antrum. In addition, they were not
significantly different from each other (Table 12). Thus, PKC/CPI-17 signaling pathway
is unlikely involved in increased tonic contraction in KPSS stimulation.

b. Rho/ROCK signaling pathway in KPSS stimulated SMB(+/+) and SMB(-/-) ileum
and antrum.

The Rho/ROCK signaling pathway is another second messenger pathway reported to
regulate tonic contraction. To test the involvement of Rho/ROCK signaling pathway in
KPSS induced increased tonic contraction in SMB(-/-) ileum and antrum, ROCK inhibitors
H1152 and Y27632 were used to eliminate tonic contraction in these tissues. Similar to
the pharmacological experiments with PKC inhibitors, the isometric force measurement
was carried out in KPSS stimulation with or without ROCK inhibitors (H1152 0.1µM,
Y27632 10µM). Results are shown in Table 11. The tonic component of contraction
induced by KPSS in tissues with H1152 or Y27632 was not decreased compared to
tissues without inhibitors. ROCK inhibitors were unable to decrease the increased tonic
contraction in SMB(-/-) ileum and antrum, indicating that Rho/ROCK may not play a role
in KPSS induced increased tonic contraction in these tissues.
Inhibitors for PKC and ROCK failed to eliminate the tonic contraction in SMB(-/-)
ileum and antrum. Force generated by specifically activating PKC with PDBu was too
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Tissue
SMB(+/+)
Ileum
SMB(-/-)
P value
SMB(+/+)
Antrum
SMB(-/-)
P value

n Area under the curve** 30 min force**
6
15.01±2.83
0.28±0.09
8
15.79±1.49
0.49±0.07
0.799
0.074
4
5.63±1.76
0.14±0.02
5
7.7±5.99
0.16±0.1
0.774
0.817

Table 12. Quantification of tonic phase activated by 1µM PDBu.
**Area under the curve was measured from peak force to 30 minutes. 30 min force is the
30 minute tonic force normalized to peak force.
Values are mean ± SE. * Significant at P< 0.05.
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(-/-)
small to account for the increased tonic component of contraction in the SMB ileum
and antrum. Thus, the increased tonic contraction of SMB(-/-) ileum and
antrum induced by KPSS was not regulated by either the PKC/CPI-17 or Rho/ROCK
signaling pathway.
2. Other contractile regulatory proteins in SMB(+/+) and SMB(-/-) ileum and antrum

The SMB(-/-) mouse model that we are working with appears anatomically and
physically normal. In order for the mouse to survive, the loss of SMB MHC isoform may
result in up or down regulation of certain proteins in SM (including the up regulation of
SMA MHC isoform). In the SMB(-/-) animal, the expression of proteins involved in
smooth muscle contractile regulation needs to be examined. Western blotting was carried
out to quantitatively compare the expression of various contractile regulatory proteins
including MLCK, MLCP, PKCδ, PKCα and CPI-17 in SMB(-/-) and SMB(+/+) ileum,
antrum and fundus, that could also be altered as a result of compensatory changes in the
SMB(-/-) mice. Results (Table 13) show that for all of the SM tissues studied, the levels of
the above mentioned proteins except PKCα were not significantly altered between the
SMB(-/-) and SMB(+/+) animals (Table 13). PKCα protein expression was significantly
reduced in the antrum, but not in the ileum or fundus of SMB(-/-) mice.
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Tissue
type

Protein

SMB
**

SMB
**

P
value

Ileum

MLCK

0.9±0.1

1.04±0.13

0.449

MLCP

1.13±0.06

1.12±0.13

0.974

PKCδ

1.09±0.26

1.09±0.31

0.997

PKCα

0.99±0.03

1.04±0.02

0.24

Representative
western blot result
SMB(+/+) SMB(-/-)
β actin
β actin
β actin
β actin

CPI-17

0.89±0.2

1.15±0.21

0.425
β actin

Antrum

MLCK

1.08±0.16

1.14±0.12

0.779
β actin

MLCP

1.06±0.07

0.95±0.07

0.286
β actin

PKCδ

1.27±0.13

1.11±0.22

0.564
β actin

PKCα

1.08±0.02

0.93±0.02

0.005*

CPI-17

1.01±0.04

0.98±0.04

0.575

MLCK

1.02±0.09

0.99±0.09

0.779

MLCP

1.13±0.29

0.85±0.06

0.401

β actin
β actin
Fundus

β actin

PKCδ

0.99±0.03

1.01±0.12

0.878

β actin
β actin

PKCα

1.03±0.06

0.98±0.06

0.585

CPI-17

1.00±0.03

1.03±0.08

0.788

β actin
β actin
Table 13. Quantitative western blot results of the expression of various contraction
regulatory proteins in SMB(+/+) and SMB(-/-) ileum, antrum and fundus with β actin as
loading control. The expression of PKCα was decreased in SMB(-/-) antrum compared to
SMB(+/+).
Values are mean ± SE. ** Arbitrary densitometric units. * Difference determined by ttest to be significant at P<0.05. n=3 for all groups.
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The mechanism underlying the sustained tonic force of smooth muscle
contraction remains unknown. The kinetics of actomyosin ATPase activity of SMA MHC
is slower than the SMB MHC isoform (Kelley et al., 1993; Sweeney et al., 1998). In
addition, SMA and SMB MHC protein expression is preferential to tonic and phasic
tissues, respectively (Babij, 1993; Eddinger and Meer, 2001; Eddinger et al., 2007;
Eddinger, 2009; Han et al., 2006; Rondelli et al., 2007; White et al., 1993). And the
SMA/B MHC isoforms are predominantly or exclusively expressed in adult animal
smooth muscle tissues(Eddinger and Murphy, 1991; Eddinger and Wolf, 1993; Giuriato
et al., 1992). Thus, we hypothesized that the SMA and SMB MHC isoforms are
responsible for regulating tonic and phasic contractions respectively in smooth muscle.
To test this hypothesis, we used SMB MHC knockout mouse (Babu et al., 2001) phasic
(ileum and antrum) and tonic tissues (fundus) to investigate whether loss of SMB MHC
protein would lead to an increased sustained tonic force and a deceased rate of force
generation in SM tissues.
The SMB(-/-) mice appear physically and anatomically normal. Histological
analysis of SMB(-/-) ileum, antrum and fundus smooth muscle layers reveals no gross
differences relative to wild type mice (Figure 7), which is consistent with previous
reports (Babu et al., 2001) suggesting that the loss of the SMB MHC isoform does not
cause muscle pathology or affect animal survival. This could be due to the compensatory
upregulation of the SMA MHC isoform, which appears to compensate in maintaining the

	
  
smooth muscle structure and function in SMB(-/-) mice.
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Phasic smooth muscle tissues such as ileum and stomach antrum express
predominantly the SMB MHC isoform. The loss of the SMB MHC isoform in these
tissues is compensated for by the upregulation of the SMA MHC isoform. Fundus, which
primarily expresses the SMA MHC isoform (Eddinger and Meer, 2001), did not show
upregulation of SMA MHC protein in the SMB(-/-) mice. Our data (Table 4) also show
that the total SM myosin (SM+NM) content is not altered in all of the three tissues,
suggesting that loss of SMB MHC is compensated for by the up regulated SMA MHC
isoform. Besides the SM MHC isoform, non-muscle (NM) MHC may also affect the
total MHC content. Furthermore, NM myosin has been reported to regulate tonic
contraction (Lofgren et al., 2003; Morano et al., 2000). Therefore, comparison of the
expression of NM MHC in SMB(+/+) and SMB(-/-) needed to be examined. Measurement
of NM MHC protein expression in the ileum shows no significant difference between the
SMB(-/-) and wild type control (Table 4). Consistently, Babu et al. (Babu et al., 2001)
also reported that the expression of NM MHC is unchanged in SMB(+/+) and SMB(-/-)
mouse bladder. Furthermore, multiple studies (Borrione et al., 1989; Eddinger and
Murphy, 1991; Eddinger and Wolf, 1993; Frid et al., 1993; Giuriato et al., 1992;
Loukianov et al., 1997) have reported that the expression of NM MHC is
developmentally regulated and not abundantly expressed in adult animal tissues. Taken
together, these data show that the SM MHC isoform in SMB(-/-) ileum and antrum
switches from SMB to SMA MHC, without a significant change in NM MHC expression.
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participate in any changes of smooth muscle contractile patterns in SMB(-/-) tissues.
If the SMA MHC is responsible for tonic contraction, it is expected that the
sustained tonic force would increase in SMB(-/-) phasic tissues where the SMB MHC
isoform switches to the SMA MHC isoform. Our data show that with KPSS stimulation,
switching from SMB to SMA MHC significantly increases the sustained tonic force in
SMB(-/-) ileum and antrum tissues (Figure 9, Table 7). Tonic fundus tissue, where there is
only limited expression of the SMB MHC isoform in SMB (+/+) animals, does not show a
significant change in tonic contraction as there is not a significant change in SMB MHC
protein expression. These data provide support for the hypothesis that the SMA MHC
isoform is a major determinant of tonic contraction.
Second messenger pathway regulation of LC20 phosphorylation has been
proposed to play an important role in tonic contraction. There have been numerous
studies reporting the involvement of PKC/CPI-17 and Rho/ROCK second messenger
pathways in regulating tonic contraction via control of LC20 phosphorylation (Ratz et al.,
2005; Somlyo and Somlyo, 2003). Jiang et al. (Jiang and Morgan, 1987) reported that the
PKC/CPI-17 signaling pathway is able to regulate tonic contraction via phorbol ester
stimulation. Work from Sohn et al. (Sohn et al., 2001) suggested that PKCε is responsible
for maintenance of tonic tone induced by PGF2α or a thromboxane analog in lower
esophageal sphincter (LES), and Poole et al. (Poole and Furness, 2007) reported that the
PKCδ isoform is able to enhance tonic contraction in guinea pig ileum. Additionally, the
Rho/ROCK signaling pathway has also been reported to be responsible for tonic
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contraction (Harnett et al., 2005; Rattan et al., 2006; Urban et al., 2003). We tested this
hypothesis by using PKC or ROCK inhibitors to block the PKC/CPI-17 or Rho/ROCK
signaling pathways respectively. Results show both PKC inhibtors (Gõ6976 - PKCα, and
PKCβ1 inhibitor, GF109203X - PKCα,-β1,-β2,γ,ε,δ inhibitor) and ROCK inhibitors (Y27632,
H1152) fail to eliminate the increased sustained tonic force in these tissues (Table 11),
suggesting that the PKC/CPI-17 and Rho/ROCK signaling pathways are not responsible
for the increased tonic contraction in the SMB(-/-) animals. Consistent with this, when
directly activating PKC with PDBu, tonic force generated by PDBu stimulation is not
different between SMB(-/-) and SMB(+/+) tissues (Table 12). In addition, only minimal
force is produced in both SMB(+/+) and SMB(-/-) tissues with PDBu activation, which is
insignificant compared to the increased KPSS tonic force in SMB(-/-) ileum and antrum.
Thus, changes in the PKC/CPI-17 and Rho/ROCK signaling pathways are unlikely to be
the cause of the increased tonic contraction observed in SMB(-/-) ileum and antrum (Table
7).
There are many other regulatory pathways that may also affect LC20
phosphorylation that we did not measure. To test for this possible effect, we examined the
LC20 phosphorylation status of SMB(-/-) and SMB(+/+) ileum, antrum and fundus at 1
minute (the most prominent point of enhanced tonic contraction in SMB(-/-) ileum and
antrum) and 10 minute (steady state tonic force) time points. The phosphorylation status
of LC20 is not different between SMB(+/+) and SMB(-/-) tissues following KPSS activation,
indicating that the increased tonic contraction in SMB(-/-) ileum and antrum is not a result
of different levels of LC20 phosphorylation (Table 6). This suggests that changes in
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responsible for the tonic contraction enhancement with KPSS activation in SMB(-/-) ileum
and antrum.

Other mechanisms hypothesized to explain tonic contraction include calponin or
caldesmon dependent actin-to- myosin cross-links (Sutherland and Walsh, 1989;
Szymanski and Tao, 1997) and cytoskeletal remodeling (Gerthoffer and Gunst, 2001; Hu
et al., 2007; Kim et al., 2008; Mehta and Gunst, 1999; Pavalko et al., 1995). It has been
reported that the thin filament regulatory protein calponin expression is increased and
caldesmon expression is decreased in the SMB(-/-) aorta (Babu et al., 2004). This occurs
without a SMB to SMA MHC expression switching and results in decreased maximal
force, suggesting that these thin filament regulatory proteins may play a role in regulating
smooth muscle contraction (Babu et al., 2004). In addition, the result from a follow-up
study in mesenteric vessels, knocking out h1-calponin in SMB(-/-) mice showed loss of
calponin is able to restore the decreased maximal force level to wild type values.
However, this result may also be caused by significantly decreased α-actin expression
and increased caldesmon in these SMB MHC and h1-calponin double knockout
mesenteric vessels (Babu et al., 2006). With limited data relative to possible changes in
α-actin, calponin and caldesmon in the SMB(-/-) mice, their possible function in tonic
force maintenance, and lack of quantitation of these proteins in this study, it remains
unclear if the enhanced tonic force of SMB(-/-) animals can also be affected by
cytoskeletal remodeling (α actin related) or altered calponin or caldesmon dependent
actin –to –myosin cross links.
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Tonic force was also measured using agonist activation. CCh, an acetylcholine

analog, is a M3 receptor agonist and the major activator of gastrointestinal smooth
muscle contraction (Furness, 2012; Kitazawa et al., 2007; Murthy, 2006). Our results
indicate no increase in the tonic contractile component of the tissues examined with the
exception of the area under the curve measurement for the ileum (Figure 12, Table 8).
Why this may be remains unclear. It could be that the M3 receptor becomes inactivated
(G-protein turns off) or calcium channels turn off ([Ca2+]i decreases). Regulation of these
systems may also contribute to whether a tissue physiologically produces tonic
contractions. It has been reported that CCh activation results in spontaneous contraction
of gastrointestinal smooth muscle (Sinn et al., 2010; Unno et al., 2006), and our force
trace data shows spontaneous contractions caused by CCh (Figure 12). The presence of
spontaneous contractions superimposed on a tonic contraction may interfere with tonic
force maintenance even though the frequency and average amplitude of the spontaneous
contractions between SMB(+/+) and SMB(-/-) ileum and antrum were not found to be
significantly different (Table 9). In addition, the unaltered spontaneous contractions in
SMB(-/-) ileum and antrum suggests that SMB MHC may not be required in order for
phasic tissues to produce the fast and transient contractions that occur during rhythmic
contraction. The “slow” myosin isoform, SMA MHC, may be capable to support these
rapid contractions.
As reported, the loss of SMB MHC isoform in the SMB(-/-) tissues also results in
down regulation of PKCα in antrum and up regulation of SMA MHC in antrum and
ileum. While this could also happen for other proteins, we did not find this to be the case
for any of the other proteins we measured (MLCK, MLCP, PKCδ, and CPI-17) (Table
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Hypolite et al. (Hypolite et al., 2009) reporting PKCα protein expression is upregulated in
detrusor smooth muscle. The difference may be tissue specific regulation of PKCα in
SMB(-/-) mice. The minimal total force generated, and lack of change in this force induced
by PDBu between SMB(+/+) and SMB(-/-) suggest the change in KPSS tonic force is not
due to the down regulation of PKCα in the antrum (Table 12).
It has been reported that maximum stress is decreased in the SMB(-/-) bladder but
increased in mesenteric vessels under depolarized conditions (Babu et al., 2001; Babu et
al., 2004). In addition, Hypolite et al. (Hypolite et al., 2009) reported that the maximum
stress of SMB(-/-) bladder detrusor smooth muscle is significantly increased over SMB(+/+)
tissue. Studies from Karagiannis et al. (Karagiannis et al., 2003) using permeabilized
bladder tissues showed that the maximum stress is not altered in SMB(-/-) bladder, and
Patzak et al. (Patzak et al., 2005) also failed to find any difference of maximal stress
induced by KCl between SMB(+/+) and SMB(-/-) afferent arterioles. Tuck et al. (Tuck et al.,
2004) also reported no significant difference in SMB(-/-) airway peak resistance in
response to methacholine. We also tried to determine if there is any correlation between
SMA/SMB MHC isoform expression and maximal force generation in the phasic ileum
and antrum and tonic fundus. Our data show that replacing the SMB MHC with the SMA
MHC isoform in ileum, antrum, and fundus does not significantly alter the maximum
stress these tissues generate when activated either by KCl or CCh (see results),
suggesting that the different kinetic properties of SMA/B MHC isoforms do not affect
smooth muscle maximum force production. It remains unclear why the results of these
studies are not consistent regarding the relationship of SMA/SMB MHC isoform
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seemingly contradictory results may be a result of different experimental methods used.
Babu and Karagiannis (Babu et al., 2004; Karagiannis et al., 2004) used skinned bladder
tissue (which layer of bladder smooth muscle was tested is not clear), and Hypolite and
colleagues (Hypolite et al., 2009) used intact longitudinal layer of detrusor smooth
muscle of bladder. Although skinned tissue is good for manipulating the [Ca2+]I, small
contractile regulatory proteins such as CaM may diffuse out from skinned tissue. In the
work by Babu et al., (2004), exogenous CaM was added to the SMB(+/+) and SMB(-/-)
tissues to compensate for CaM loss. Whether the exogenous CaM is able to redistribute
to the correct cellular location and function as the endogenous CaM is unclear.
Furthermore, they did not take into consideration the expression of CaM may be altered
in intact SMB(-/-) tissue compared to SMB(+/+). Thus, studies in intact tissue are more
physiological. Reported differences between studies on small arteries using SMB(-/-)
mice also suggest differences of maximal arteriole stress(Babu et al., 2001; Babu et al.,
2004; Tuck et al., 2004). Differences here could be due to different arterioles studied
(Buba et al., 2004: mesenteric vessel, Tuck et al., 2004: renal afferent and efferent
arterioles). In addition, Tuck et al., 2004 did not directly measure force generation from
these renal arterioles but established a relationship between lumen diameter and pressure
applied. They assumed that an index of lumen diameter reflected the force generation in
these arterioles. However, while there may be a correlation between lumen diameter and
wall stress, other factors including the intracellular elastic component and extracellular
matrix also contribute to wall stress, in a non linear fashion, especially at extreme
conditions. Thus, the alteration of lumen diameter is indicative of but not the same as the
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isometric force of mesenteric vessel in SMB(+/+) and SMB(-/-).
To estimate whether SMA/SMB MHC isoforms affect Vmax in phasic and tonic
gastrointestinal tissues, we used three measurements to compare the isometric force
transient (as an estimate of Vmax) with either KPSS or CCh stimulation in SMB(+/+) and
SMB(+/+) ileum antrum, and fundus. Our results show that the force transient is
significantly slower in SMB(-/-) ileum and antrum (Table 5). This is consistent with the
results from other studies reporting a decreased Vmax using this SMB(-/-) mouse model
(Babu et al., 2001; Babu et al., 2004; Babu et al., 2006; Hypolite et al., 2009; Karagiannis
et al., 2003; Karagiannis et al., 2004; Tuck et al., 2004), and results that the SMB MHC
isoform has a two-fold greater ATPase activity and moves actin filament 2.5 folds faster
than SMA MHC in an in vitro motility assay (Kelley et al., 1993; Sweeney et al., 1998).
Because the rate of the force transient is also correlated with LC20 phosphorylation, we
also measured this. LC20 phosphorylation induced by KPSS at 5 seconds following tissue
activation is not different between the SMB(+/+) and SMB(-/-) tissues suggesting the slower
force transient in SMB(-/-) ileum and antrum is not caused by lower LC20 phosphorylation
(Table 6). The decreased force transient is correlated with and perhaps caused by the
slower kinetic properties of SMA MHC, and not a difference in LC20 phosphorylation.
The isometric force transient of fundus does not change, which is consistent with no
detectable SMB to SMA MHC protein expression switching in this tissue. The slow vs.
fast actomyosin ATPase activity of SMA/SMB MHC isoform may be important for SMA
MHC to maintain force in tonic tissues. Slow kinetics of actomyosin ATPase could result
in high ADP affinity and a low rate of ADP release in the presence of actin, which
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enables SMA MHC to remain attached to actin longer. The actin-myosin- ADP state of
SMA MHC has been reported to require mechanical strain to release ADP (Kovacs et al.,
2007). With tonic force maintenance, the long attachment time of SMA MHC to actin
may explain the hypothesized latch cross bridge.
Our study based on SMB(-/-) mice shows SMB MHC expression is turned off and
SMA MHC isoform expression is increased in SMB(-/-) phasic ileum and antrum tissues.
The reduced rate of force generation in the ileum and antrum is likely a result of the
increased expression of the SMA MHC protein that cannot generate phasic force as
quickly as the SMB MHC isoform. The increased SMA MHC expression enhances the
sustained tonic contraction observed in these phasic tissues, suggesting SMA MHC
isoform is a major determinant of tonic contraction. Further work is required to uncover
the mechanism by which SMA MHC isoform reduces the rate of tension development
and decreases Vmax and unequivocally determine whether other thin filament regulatory
proteins and cytoskeletal remodeling mechanisms also contribute to increased tonic
contraction observed in SMB(-/-) phasic tissues.
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The major goal of this project was to test the hypothesis that the tissue specific
distribution and kinetic properties of SMA and SMB MHC play a role in tonic vs. phasic
contraction. A SMB(-/-) mouse model was used in this study with these mice appearing
physically, anatomically and histologically normal. The lack of grossly observable
pathological conditions may be attributable to up regulation of the SMA MHC isoform
which compensates for the loss of SMB MHC isoform in these animals. Mechanical
changes observed in the SMB (-/-) animals include: (1) In the absence of SMB MHC, the
maximal stress induced either by KPSS or CCh stimulation was not altered in phasic
tissues (ileum and antrum). As expected, the isometric force transient rate was decreased
in these tissues, in which compensatory upregulation of the “slow” SMA replaced the
“fast” SMB MHC isoform. These results suggest that the SMA MHC isoform is able to
generate the same amount of force but with a slower dp/dt than the SMB MHC; (2) The
loss of SMB MHC and up regulated SMA MHC isoform expression resulted in elevated
tonic force maintenance with KPSS activation in SMB(-/-) ileum and antrum suggesting a
role in tonic contraction regulation. As a negative control, tonic fundus did not show any
different in contractions between SMB(+/+) and SMB(-/-) tissues. Furthermore, the
increased tonic force maintenance in these tissues was not the result of the changes in
LC20 phosphorylation or the extensively studied second messenger pathways PKC/CPI17
or Rho/ROCK; (3) The spontaneous contractions (phasic contractions) induced by CCh
in SMB(-/-) ileum and antrum were not affected either in its frequency or amplitude.
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These results suggest that (a) SMB MHC is not required for a phasic

contraction but the rate of tension generation is reduced in the absence of SMB MHC.
SMA MHC is able to generate the same amount of maximum force as SMB MHC during
phasic contraction. The slower force developmental rate in tissue expression only SMA
MHC does not affect normal physiological function of these tissues. (b) SMA MHC is
responsible for tonic contraction when ileum and antrum are fully activated by KPSS.
This study also showed that up regulated SMA MHC failed to cause increased tonic force
maintenance in SMB(-/-) ileum and antrum when stimulated with the physiological agonist
CCh. While the reason for this is not completely clear, it is possible that unloading stress
at the cross bridge during a tonic contraction (via the superimposed spontaneous
contractions) allows cross bridge to dissociate and therefore reduces tonic force
maintenance or it could be that the receptors become inactivated, that G proteins turn off,
or that calcium channels turned off, which could mask the effect of increased SMA MHC
expression. Thus it may be that the SMA MHC is required for enhanced tonic force, but
this only occurs when the proper regulatory pathways are also invoked to bring about this
maintained force generation. (c) Spontaneous contractions are critical for gastrointestinal
peristalsis and food digestion. Unaltered spontaneous contractions insure the normal
physiological function of gastrointestinal system in SMB(-/-) animal.
As mentioned above, the fact that SMB(-/-) animals appear normal suggested that
SMB MHC function can be replaced by SMA MHC under nonstressed conditions. It is
unclear if SMB(-/-) mice would show dysfunction under stressed conditions such as
reduced caloric intakes , hypoxia, extreme exertion, or with certain diseases. This study

	
  
provides clues to address this question. Changes in the myosin isoforms in
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hypertrophy related diseases have been reported in skeletal(D'Antona et al., 2006; Stone
et al., 1996), cardiac(Pandya et al., 2006; Pandya et al., 2008; Sucharov et al., 2004), and
smooth muscle(Austin et al., 2004; DiSanto et al., 2003; Lofgren et al., 2002; Wetzel et
al., 1998). Partial bladder outlet obstruction (PBOO) induced hypertrophy in mice and
rabbits results in a shift from SMB MHC to SMA MHC (DiSanto et al., 2003). The
expression of SMB MHC in precapillary arterioles of left ventricle of the spontaneous
hypertensive rats is also significantly decreased (Wetzel et al., 1998). Down regulated
SMB MHC was also observed in the mega colon in Hirschsprang’s disease and partial
obstructive ileum (Lofgren et al., 2002; Siegman et al., 1997). Results from our study
demonstrating a slower force transient rate of SMA MHC correlated with lower ATPase
activity (Kelley et al., 1993; Sweeney et al., 1998) seem to not affect the normal
physiological function of SMB (-/-) smooth muscle tissues, indicating that SMA MHC
may substitute for SMB MHC in a more energy efficient manner. Thus we speculate that
under unfavorable conditions, smooth muscle may switch its myosin heavy chain
composition from SMB MHC to the more economical SMA MHC to conserve energy.
This could explain the observations that hypertrophied detrusor smooth muscle (DSM),
ileum smooth muscle and mega colon in Hirschsprang’s disease or cardiac vessels of
hypertensive rats have decreased SMB MHC expression.
Our study suggested that SMA MHC is able to maintain force at a higher level
than SMB MHC, which propose possible explanation for a common phenomenon in
smooth muscle hypertrophy that SMB MHC isoform changes towards to SMA MHC.
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(Sjuve et al., 1998) In hypertrophic organs, the tension generated from smooth muscle
wall must be increased to maintain a given intraluminal pressure. The change in
contractile properties from SMB to SMA MHC isoform might be beneficial in such
conditions where the tension needs to be maintained for longer period of time
Besides disease pathology, further test for whether SMA MHC is able to
completely replace SMB MHC and maintain normal physiological function in smooth
muscle tissues, could focus on effects of stress conditions (coloric restriction, hypoxia,
pH etc.) on smooth muscle contractile characteristics as well as the overall performance
of SMB(-/-) mice on vomiting, constipation, diarrhea, etc.
This study provided information about the distribution and kinetic properties of
SMA and SMB MHC isoforms in regulating tonic and phasic contractile patterns in
smooth muscle tissues. It also provided insight to correlate SMA/B MHC isoforms with
disease pathology such as hypertrophy. The results that SMA MHC is able to replace
SMB MHC in maintaining maximum force generation while increasing efficiency makes
SMA MHC a more favorable MHC isoform under stressed conditions, which is very
interesting and worth investigating.
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